2022/02/02 更新

写真a

ミチウエ ヒロユキ
道上 宏之
MICHIUE Hiroyuki
所属
中性子医療研究センター 准教授
職名
准教授
外部リンク

学位

  • 医学博士 ( 2005年6月   岡山大学 )

研究キーワード

  • 悪性脳腫瘍

  • ホウ素中性子捕捉療法

  • 細胞膜通過ペプチド

  • ペプチド創薬

  • 既存薬再開発

  • 膠芽腫

  • 細胞浸潤

  • アクチン重合

  • 癌幹細胞

  • 脳腫瘍幹細胞

  • ドラッグデリバリーシステム

  • 血液脳関門

  • 免疫複合療法

  • ホウ素薬剤

  • 悪性黒色腫

研究分野

  • ライフサイエンス / 脳神経外科学  / 悪性脳腫瘍

  • ライフサイエンス / 腫瘍生物学  / 既存薬再開発

  • ナノテク・材料 / ナノバイオサイエンス  / ペプチド創薬

  • ライフサイエンス / 薬系化学、創薬科学  / ホウ素薬剤創薬

  • ライフサイエンス / 皮膚科学  / 悪性黒色腫へのホウ素中性子捕捉療法

  • ライフサイエンス / 腫瘍診断、治療学  / ホウ素中性子捕捉療法

  • ライフサイエンス / 消化器外科学  / 膵癌標的治療 / CA19-9

▼全件表示

学歴

  • 岡山大学   Graduate School of Medicine , Dentistry and Pharmaceutical Sciences   doctor course

    1999年4月 - 2005年6月

      詳細を見る

    国名: 日本国

    備考: M.D. Ph.D

    researchmap

  • 岡山大学   Medical School   Faculty of Medicine

    1993年4月 - 1999年3月

      詳細を見る

    国名: 日本国

    researchmap

経歴

  • 岡山大学   中性子医療研究センター   准教授

    2017年4月 - 現在

      詳細を見る

    国名:日本国

    researchmap

  • 岡山大学   大学院医歯薬学総合研究科   助教

    2010年4月 - 2017年3月

      詳細を見る

    国名:日本国

    researchmap

  • 岡山大学   大学院医歯薬学総合研究科   助教

    2007年11月 - 2010年3月

      詳細を見る

    国名:日本国

    researchmap

  • カルフォルニア大学サンディエゴ校   医学部   研究員

    2005年6月 - 2007年10月

      詳細を見る

    国名:日本国

    researchmap

  • 岡山大学   医学部附属病院   医師

    2001年11月 - 2002年10月

      詳細を見る

    国名:日本国

    researchmap

  • 松山市民病院   脳神経外科   医師

    1999年11月 - 2001年10月

      詳細を見る

    国名:日本国

    researchmap

  • 岡山大学   医学部附属病院   医師

    1999年6月 - 1999年10月

      詳細を見る

    国名:日本国

    researchmap

▼全件表示

所属学協会

  • 日本癌学会

    2018年7月 - 現在

      詳細を見る

  • 日本中性子捕捉療法学会

    2009年4月 - 現在

      詳細を見る

  • 日本生理学会

    2006年10月 - 現在

      詳細を見る

  • 日本脳腫瘍学会

    2003年11月 - 現在

      詳細を見る

  • 日本脳卒中学会

    2003年4月 - 現在

      詳細を見る

  • 日本脳神経外科学会

    2000年4月 - 現在

      詳細を見る

▼全件表示

委員歴

  • ナノ・バイオ融合によるエネルギー集積・高度利用研究拠点形成   シンポジウムオーガナイザー  

    2021年3月 - 現在   

      詳細を見る

    団体区分:その他

    researchmap

  • 日本中性子捕捉療法学会   監事  

    2020年6月 - 現在   

      詳細を見る

    団体区分:学協会

    researchmap

  • 日本生理学会中国四国支部   中国四国支部幹事  

    2014年4月 - 現在   

      詳細を見る

 

論文

  • Complementary leucine zippering system for effective intracellular delivery of proteins by cell-penetrating peptides. 国際誌

    Mizuki Kitamatsu, Hiroki Yuasa, Takashi Ohtsuki, Hiroyuki Michiue

    Bioorganic & medicinal chemistry   33   116036 - 116036   2021年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    A heterodimeric leucine zipper composed of a pair of leucine zipper peptides containing acidic or basic amino acid residues at appropriate positions in each peptide was used as a molecular glue to connect protein cargos to a cell-penetrating peptide (CPP) carrier. To investigate the hybridization properties by fluorescence experiments, we prepared an enhanced green fluorescent protein (EGFP) fused with an acidic leucine zipper (LzK), EGFP-LzK, and a basic leucine zipper (LzE) modified with a CPP, LzE-CPP. The LzK and LzE formed a 1:1 hybrid when EGFP-LzK and LzE-CPP were mixed in phosphate buffer saline, thereby conjugating the EGFP with the CPP. The formation of the 1:1 hybrid was confirmed by fluorescence spectra and fluorescence titration curves. Results from fluorescence microscopy experiments showed that EGFP was successfully delivered into cells by conjugating with the CPP via formation of the LzK/LzE hybrid. We also fused the apoptotic protein p53 with LzK (p53-LzK) and investigated the inhibition of cell proliferation of various cell lines by incubation with the p53-LzK/LzE-CPP hybrid. This hybrid was found to localize in nuclei and successfully inhibited cell-specific proliferation. The LzE/LzK zipper system inhibited cell proliferation more efficiently than the directly fused conjugate, p53-CPP. Our method will be a useful drug delivery system for delivering bioactive proteins to treat various diseases.

    DOI: 10.1016/j.bmc.2021.116036

    PubMed

    researchmap

  • Self-assembling A6K peptide nanotubes as a mercaptoundecahydrododecaborate (BSH) delivery system for boron neutron capture therapy (BNCT). 国際誌

    Hiroyuki Michiue, Mizuki Kitamatsu, Asami Fukunaga, Nobushige Tsuboi, Atsushi Fujimura, Hiroaki Matsushita, Kazuyo Igawa, Tomonari Kasai, Natsuko Kondo, Hideki Matsui, Shuichi Furuya

    Journal of controlled release : official journal of the Controlled Release Society   330   788 - 796   2021年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Boron neutron capture therapy (BNCT) is a tumor selective therapy, the effectiveness of which depends on sufficient 10B delivery to and accumulation in tumors. In this study, we used self-assembling A6K peptide nanotubes as boron carriers and prepared new boron agents by simple mixing of A6K and BSH. BSH has been used to treat malignant glioma patients in clinical trials and its drug safety and availability have been confirmed; however, its contribution to BNCT efficacy is low. A6K nanotube delivery improved two major limitations of BSH, including absence of intracellular transduction and non-specific drug delivery to tumor tissue. Varying the A6K peptide and BSH mixture ratio produced materials with different morphologies-determined by electron microscopy-and intracellular transduction efficiencies. We investigated the A6K/BSH 1:10 mixture ratio and found high intracellular boron uptake with no toxicity. Microscopy observation showed intracellular localization of A6K/BSH in the perinuclear region and endosome in human glioma cells. The intracellular boron concentration using A6K/BSH was almost 10 times higher than that of BSH. The systematic administration of A6K/BSH via mouse tail vein showed tumor specific accumulation in a mouse brain tumor model with immunohistochemistry and pharmacokinetic study. Neutron irradiation of glioma cells treated with A6K/BSH showed the inhibition of cell proliferation in a colony formation assay. Boron delivery using A6K peptide provides a unique and simple strategy for next generation BNCT drugs.

    DOI: 10.1016/j.jconrel.2020.11.001

    PubMed

    researchmap

  • Improvement of water solubility of mercaptoundecahydrododecaborate (Bsh)-peptides by conjugating with ethylene glycol linker and interaction with cyclodextrin

    Mizuki Kitamatsu, Ayaka Nakamura-Tachibana, Yoshimichi Ishikawa, Hiroyuki Michiue

    Processes   9 ( 1 )   1 - 11   2021年1月

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    We previously developed a conjugate consisting of B cluster BSH and tri-arginine peptide (BSH-3R). This could potentially be used as a boron agent for boron neutron capture therapy; however, it possesses poor water solubility and thus needs to be improved for use as medicine. In this study, we devised several means of improving the water solubility of BSH-3R. As one of them, we used cyclodextrin (CD), which was expected to improve the water solubility resulting from interaction of the BSH-3R with CD. We evaluated the solubility of BSH-3R in aqueous CD solution by using reverse-phase high-performance liquid chromatography. As we expected, the solubility of BSH-3R was increased in a manner dependent on the addition of β-CD and γ-CD in aqueous solution. Furthermore, we synthesized BSH conjugated to oligoarginine having various chain lengths (BSH-nR) and BSH-3R with ethylene glycol linkers introduced between BSH and 3R (BSH-nEg-3R). The water solubility of these BSH peptides was also evaluated and the results showed that the introduction of nEg to BSH-3R markedly improved the water solubility. Furthermore, we found that the water solubility of these peptides can be further improved by also applying CD. 10

    DOI: 10.3390/pr9010167

    Scopus

    researchmap

  • 細胞内局在を標的とした新規ホウ素製剤が切り拓く次世代BNCT

    藤村 篤史, 井川 和代, 植田 愛, 渡辺 香里, 道上 宏之, 市川 康明, 古矢 修一

    Medical Science Digest   46 ( 8 )   535 - 537   2020年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)ニュー・サイエンス社  

    病院設置型のBPA-BNCT治療システムがいよいよ社会実装されるに至った。今後BNCTががん治療法の一端を担うことになると広く期待されているが、一方で、現行のホウ素薬剤BPAによるホウ素送達が適していないがん種や症例に対しては、異なるメカニズムを有した新たなホウ素製剤の開発が必要である。BPA-BNCTは、F-BPAを用いたPET検査により適応可否が判断できる治療システムであるが、後続するホウ素製剤においても同様に患者層別化が可能であることが求められる。本稿では、我々が最近開発に取り組んでいるBSH製剤を例に、これからのホウ素製剤を用いたBNCTが患者層別化可能な治療法であるためには、どのような観点から開発に取り組むべきかを考察したい。(著者抄録)

    researchmap

  • A leucine zipper-based peptide hybrid delivers functional Nanog protein inside the cell nucleus. 査読 国際誌

    Yoshiyuki Hakata, Hiroyuki Michiue, Takashi Ohtsuki, Masaaki Miyazawa, Mizuki Kitamatsu

    Bioorganic & medicinal chemistry letters   29 ( 7 )   878 - 881   2019年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    We synthesized a pair of compounds containing leucine zipper peptides to deliver protein cargo into cells. One is a cell-penetrating peptide (CPP) with Lz(E), a leucine zipper peptide containing negatively charged amino acids, and the other is a Nanog protein with Lz(K), a leucine zipper peptide containing positively charged amino acids. When cells were treated with these equimolar mixtures, Nanog-Lz(K) hybridized with Lz(E)-CPP was successfully delivered into the cells. Furthermore, Nanog-Lz(K) exerted its proper function after nuclear transport.

    DOI: 10.1016/j.bmcl.2019.02.004

    PubMed

    researchmap

  • Physical modification of carbon nanotubes with a dendrimer bearing terminal mercaptoundecahydrododecaborates (Na2B12H11S) 査読

    Masahiro Yamagami, Tomoyuki Tajima, Kango Ishimoto, Hideaki Miyake, Hiroyuki Michiue, Yutaka Takaguchi

    HETEROATOM CHEMISTRY   29 ( 5-6 )   2018年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-HINDAWI  

    The thiol-substituted B-12-cluster mercaptoundecahydro-closo-dodecaborate Na-2[B12H11SH] (BSH) was successfully attached to a poly(amido)amine (PAMAM) dendrimer, which contains a bis(decyloxy)decane core. The physical modification of single-walled carbon nanotubes (SWCNTs) with dendrimer(SB12)(4) afforded a SWCNT/dendrimer(SB12)(4) nanohybrid that exhibited NIR-I-to-NIR-II fluorescence. Herein, we describe a promising strategy for in vivo imaging of boron clusters that may be widely applicable to boron neutron capture therapy.

    DOI: 10.1002/hc.21467

    Web of Science

    researchmap

  • Boron Neutron Capture Therapy Combined with Early Successive Bevacizumab Treatments for Recurrent Malignant Gliomas - A Pilot Study 査読

    Hiroyuki Shiba, Koji Takeuchi, Ryo Hiramatsu, Motomasa Furuse, Naosuke Nonoguchi, Shinji Kawabata, Toshihiko Kuroiwa, Natsuko Kondo, Yoshinori Sakurai, Minoru Suzuki, Koji Ono, Shiro Oue, Eiichi Ishikawa, Hiroyuki Michiue, Shin-Ichi Miyatake

    NEUROLOGIA MEDICO-CHIRURGICA   58 ( 12 )   487 - 494   2018年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:JAPAN NEUROSURGICAL SOC  

    Recurrent malignant gliomas (RMGs) are difficult to control, and no standard protocol has been established for their treatment. At our institute, we have often treated RMGs by tumor-selective particle radiation called boron neutron capture therapy (BNCT). However, despite the cell-selectivity of BNCT, brain radiation necrosis (BRN) may develop and cause severe neurological complications and sometimes death. This is partly due to the full-dose X-ray treatments usually given earlier in the treatment course. To overcome BRN following BNCT, recent studies have used bevacizumab (BV). We herein used extended BV treatment beginning just after BNCT to confer protection against or ameliorate BRN, and evaluated; the feasibility, efficacy, and BRN control of this combination treatment. Seven patients with RMGs (grade 3 and 4 cases) were treated with BNCT between June 2013 and May 2014, followed by successive BV treatments. They were followed-up to December 2017. Median overall survival (OS) and progression-free survival (PFS) after combination treatment were 15.1 and 5.4 months, respectively. In one case, uncontrollable brain edema occurred and ultimately led to death after BV was interrupted due to meningitis. In two other cases, symptomatic aggravation of BRN occurred after interruption of BV treatment. No BRN was observed during the observation period in the other cases. Common terminology criteria for adverse events grade 2 and 3 proteinuria occurred in two cases and necessitated the interruption of BV treatments. Boron neutron capture therapy followed by BV treatments well-prevented or well-controlled BRN with prolonged OS and acceptable incidence of adverse events in our patients with RMG.

    DOI: 10.2176/nmc.oa.2018-0111

    Web of Science

    PubMed

    researchmap

  • Oxytocin Inhibits Corticosterone-induced Apoptosis in Primary Hippocampal Neurons. 査読 国際誌

    Hein Min Latt, Hiroaki Matsushita, Miku Morino, Yuuri Koga, Hiroyuki Michiue, Teiichi Nishiki, Kazuhito Tomizawa, Hideki Matsui

    Neuroscience   379   383 - 389   2018年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Stress is an adaptive and coordinated response to endogenous or exogenous stressors that pose an unpleasant and aversive threat to an individual's homeostasis and wellbeing. Glucocorticoids, corticosterone (CORT) in rodents and cortisol in humans, are adrenal steroids which are released in response to stressful stimuli. Although they help individuals to cope with stress, their overexposure in animals has been implicated in hippocampal dysfunction and neuronal loss. Oxytocin (OT) plays an active role in adaptive stress-related responses and protects hippocampal synaptic plasticity and memory during stress. In this study, we showed that OT protects primary mouse hippocampal neurons from CORT-induced apoptosis. OT receptors (OTR) were expressed in primary mouse hippocampal neurons and glial cells. CORT induced apoptosis in hippocampal neurons, but had no effect on apoptosis in glial cells. OT inhibited CORT-induced apoptosis in primary hippocampal neurons. OT was unable to protect primary hippocampal neurons prepared from OTR KO mice from CORT-induced apoptosis. These results indicate that OT has inhibitory effects on CORT-induced neuronal death in primary hippocampal neurons via acting on OTR. The findings suggest a therapeutic potential of OT in the treatment of stress-related disorders.

    DOI: 10.1016/j.neuroscience.2018.03.025

    PubMed

    researchmap

  • Fibroblast growth factor 13 regulates glioma cell invasion and is important for bevacizumab-induced glioma invasion. 査読 国際誌

    Y Otani, T Ichikawa, K Kurozumi, S Inoue, J Ishida, T Oka, T Shimizu, Y Tomita, Y Hattori, A Uneda, Y Matsumoto, H Michiue, I Date

    Oncogene   37 ( 6 )   777 - 786   2018年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Glioblastoma has the poorest prognosis, and is characterized by excessive invasion and angiogenesis. To determine the invasive mechanisms, we previously used two glioma cell lines (J3T-1 and J3T-2) with different invasive phenotypes. The J3T-1 showed abundant angiogenesis and tumor cell invasion around neovasculature, while J3T-2 showed diffuse cell infiltration into surrounding healthy parenchyma. Microarray analyses were used to identify invasion-related genes in J3T-2 cells, and the expressed genes and their intracellular and intratumoral distribution patterns were evaluated in J3T-2 cell lines, human glioma cell lines, human glioblastoma stem cells and human glioblastoma specimens. To determine the role of the invasion-related genes, invasive activities were evaluated in vitro and in vivo. Fibroblast growth factor 13 (FGF13) was overexpressed in J3T-2 cells compared to J3T-1 cells, and in human glioma cell lines, human glioblastoma stem cells and human glioblastoma specimens, when compared to that of normal human astrocytes. Immunohistochemical staining and the RNA-seq (sequencing) data from the IVY Glioblastoma Atlas Project showed FGF13 expression in glioma cells in the invasive edges of tumor specimens. Also, the intracellular distribution was mainly in the cytoplasm of tumor cells and colocalized with tubulin. Overexpression of FGF13 stabilized tubulin dynamics in vitro and knockdown of FGF13 decreased glioma invasion both in vitro and in vivo and prolonged overall survival of several xenograft models. FGF13 was negatively regulated by hypoxic condition. Silencing of FGF13 also decreased in vivo bevacizumab-induced glioma invasion. In conclusion, FGF13 regulated glioma cell invasion and bevacizumab-induced glioma invasion, and could be a novel target for glioma treatment.

    DOI: 10.1038/onc.2017.373

    PubMed

    researchmap

  • FIBROBLAST GROWTH FACTOR 13 REGULATES GLIOMA CELL INVASION 査読

    Yoshihiro Otani, Tomotsugu Ichikawa, Kazuhiko Kurozumi, Satoshi Inoue, Joji Ishida, Tetsuo Oka, Toshihiko Shimizu, Yusuke Tomita, Yasuhiko Hattori, Atsuhito Uneda, Yuji Matsumoto, Hiroyuki Michiue, Isao Date

    NEURO-ONCOLOGY   19   21 - 21   2017年11月

     詳細を見る

    記述言語:英語   出版者・発行元:OXFORD UNIV PRESS INC  

    Web of Science

    researchmap

  • PIK3R1Met326Ile germline mutation correlates with cysteine-rich protein 61 expression and poor prognosis in glioblastoma 査読 国際誌

    Yoshihiro Otani, Joji Ishida, Kazuhiko Kurozumi, Tetsuo Oka, Toshihiko Shimizu, Yusuke Tomita, Yasuhiko Hattori, Atsuhito Uneda, Yuji Matsumoto, Hiroyuki Michiue, Shuta Tomida, Takehiro Matsubara, Tomotsugu Ichikawa, Isao Date

    SCIENTIFIC REPORTS   7 ( 1 )   7391 - 7391   2017年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:NATURE PUBLISHING GROUP  

    Despite therapeutic advances, glioblastoma represents a lethal brain tumor. Recently, research to identify prognostic markers for glioblastoma has intensified. Our previous study demonstrated that median progression-free survival (PFS) and overall survival (OS) of patients with high cysteine-rich protein 61 (CCN1) expression was significantly shorter than that of patients with low CCN1 expression. To understand the molecular mechanisms that regulate CCN1 expression, we examined 147 tumour samples from 80 patients with glioblastoma and 67 patients with lower grade glioma. Next-generation and Sanger sequencing showed that PIK3R1Met326Ile was more frequent in the CCN1 high expression group (10/37 cases, 27.0%) than the CCN1 low expression group (3/38 cases, 7.9%) in glioblastoma. This mutation was also detected in corresponding blood samples. In multivariate analysis, high CCN1 expression and PIK3R1Met326Ile in glioblastoma patients were prognostic factors for OS [HR = 2.488 (1.298-4.769), p = 0.006] and [HR = 2.089 (1.020-4.277), p = 0.0439], respectively. Thus, the PIK3R1Met326Ile germline appears to be correlated with CCN1 expression and poor prognosis in glioblastoma.

    DOI: 10.1038/s41598-017-07745-0

    Web of Science

    PubMed

    researchmap

  • Actin bundling by dynamin 2 and cortactin is implicated in cell migration by stabilizing filopodia in human non-small cell lung carcinoma cells 査読 国際誌

    Hiroshi Yamada, Tetsuya Takeda, Hiroyuki Michiue, Tadashi Abe, Kohji Takei

    INTERNATIONAL JOURNAL OF ONCOLOGY   49 ( 3 )   877 - 886   2016年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPANDIDOS PUBL LTD  

    The endocytic protein dynamin participates in the formation of actin-based membrane protrusions such as podosomes, pseudopodia, and invadopodia, which facilitate cancer cell migration, invasion, and metastasis. However, the role of dynamin in the formation of actin-based membrane protrusions at the leading edge of cancer cells is unclear. In this study, we demonstrate that the ubiquitously expressed dynamin 2 isoform facilitates cell migration by stabilizing F-actin bundles in filopodia of the lung cancer cell line H1299. Pharmacological inhibition of dynamin 2 decreased cell migration and filopodial formation. Furthermore, dynamin 2 and cortactin mostly colocalized along F-actin bundles in filopodia of serum-stimulated H1299 cells by immunofluorescent and immunoelectron microscopy. Knockdown of dynamin 2 or cortactin inhibited the formation of filopodia in serum-stimulated H1299 cells, concomitant with a loss of F-actin bundles. Expression of wild-type cortactin rescued the punctate-like localization of dynamin 2 and filopodial formation. The incubation of dynamin 2 and cortactin with F-actin induced the formation of long and thick actin bundles, with these proteins colocalizing at F-actin bundles. A depolymerization assay revealed that dynamin 2 and cortactin increased the stability of F-actin bundles. These results indicate that dynamin 2 and cortactin participate in cell migration by stabilizing F-actin bundles in filopodia. Taken together, these findings suggest that dynamin might be a possible molecular target for anticancer therapy.

    DOI: 10.3892/ijo.2016.3592

    Web of Science

    PubMed

    researchmap

  • Fluvoxamine, an anti-depressant, inhibits human glioblastoma invasion by disrupting actin polymerization. 査読 国際誌

    Keiichiro Hayashi, Hiroyuki Michiue, Hiroshi Yamada, Katsuyoshi Takata, Hiroki Nakayama, Fan-Yan Wei, Atsushi Fujimura, Hiroshi Tazawa, Akira Asai, Naohisa Ogo, Hiroyuki Miyachi, Tei-ichi Nishiki, Kazuhito Tomizawa, Kohji Takei, Hideki Matsui

    Scientific reports   6   23372 - 23372   2016年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Glioblastoma multiforme (GBM) is the most common malignant brain tumor with a median survival time about one year. Invasion of GBM cells into normal brain is the major cause of poor prognosis and requires dynamic reorganization of the actin cytoskeleton, which includes lamellipodial protrusions, focal adhesions, and stress fibers at the leading edge of GBM. Therefore, we hypothesized that inhibitors of actin polymerization can suppress GBM migration and invasion. First, we adopted a drug repositioning system for screening with a pyrene-actin-based actin polymerization assay and identified fluvoxamine, a clinically used antidepressant. Fluvoxamine, selective serotonin reuptake inhibitor, was a potent inhibitor of actin polymerization and confirmed as drug penetration through the blood-brain barrier (BBB) and accumulation of whole brain including brain tumor with no drug toxicity. Fluvoxamine inhibited serum-induced ruffle formation, cell migration, and invasion of human GBM and glioma stem cells in vitro by suppressing both FAK and Akt/mammalian target of rapamycin signaling. Daily treatment of athymic mice bearing human glioma-initiating cells with fluvoxamine blocked tumor cell invasion and prolonged the survival with almost same dose of anti-depressant effect. In conclusion, fluvoxamine is a promising anti-invasive treatment against GBM with reliable approach.

    DOI: 10.1038/srep23372

    PubMed

    researchmap

  • Detection of γH2AX foci in mouse normal brain and brain tumor after boron neutron capture therapy 査読

    21 ( 2 )   108 - 112   2016年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.rpor.2014.10.005

    Scopus

    researchmap

  • Tumor-specific delivery of BSH-3R for boron neutron capture therapy and positron emission tomography imaging in a mouse brain tumor model. 査読 国際誌

    Yoshiya Iguchi, Hiroyuki Michiue, Mizuki Kitamatsu, Yuri Hayashi, Fumiaki Takenaka, Tei-Ichi Nishiki, Hideki Matsui

    Biomaterials   56   10 - 7   2015年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Glioblastoma, a malignant brain tumor with poor disease outcomes, is managed in modern medicine by multimodality therapy. Boron neutron capture therapy (BNCT) is an encouraging treatment under clinical investigation. In malignant cells, BNCT consists of two major factors: neutron radiation and boron uptake. To increase boron uptake in cells, we created a mercapto-closo-undecahydrododecaborate ([B12HnSH](2-)2Na(+), BSH) fused with a short arginine peptide (1R, 2R, 3R) and checked cellular uptake in vitro and in vivo. In a mouse brain tumor model, only BSH with at least three arginine domains could penetrate cell membranes of glioma cells in vitro and in vivo. Furthermore, to monitor the pharmacokinetic properties of these agents in vivo, we fused BSH and BSH-3R with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA); DOTA is a metal chelating agent for labeling positron emission tomography (PET) probe with (64)Cu. We administered BSH-DOTA-(64)Cu and BSH-3R-DOTA-(64)Cu to the tumor model through a mouse tail vein and determined the drugs' pharmacokinetics by PET imaging. BSH-3R showed a high uptake in the tumor area on PET imaging. We concluded that BSH-3R is the ideal boron compound for clinical use during BNCT and that in developing this compound for clinical use, the BSH-3R PET probe is essential for pharmacokinetic imaging.

    DOI: 10.1016/j.biomaterials.2015.03.061

    PubMed

    researchmap

  • Annexin A2 regulates angiogenesis and invasion phenotypes of malignant glioma 査読

    Manabu Onishi, Tomotsugu Ichikawa, Kazuhiko Kurozumi, Satoshi Inoue, Tomoko Maruo, Yoshihiro Otani, Kentaro Fujii, Joji Ishida, Yosuke Shimazu, Koichi Yoshida, Hiroyuki Michiue, E. Antonio Chiocca, Isao Date

    BRAIN TUMOR PATHOLOGY   32 ( 3 )   184 - 194   2015年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPRINGER JAPAN KK  

    We have established a pair of animal models (J3T-1 and J3T-2) with different invasive and angiogenic phenotypes, and demonstrated that annexin A2 is expressed at higher levels in J3T-1 than J3T-2 cells. The function of annexin A2 in relation to angiogenesis and invasion was investigated using these models. Stable silencing or overexpression of annexin A2 in J3T-1 and J3T-2 cells (J3T-1shA and J3T-2A cells) was established and used. Thirty human glioblastoma samples were evaluated for expression of annexin A2, vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). Immunohistochemical and quantitative reverse-transcription polymerase chain reaction analyses revealed higher expression of annexin A2, VEGF and PDGF in J3T-1 and J3T-2A cells. Cultured J3T-1 and J3T-2A cells exhibited higher adhesive ability to endothelial cells. Histopathological analysis of animal brain tumors revealed that J3T-1 and J3T-2A tumors displayed marked angiogenesis and invasion along the neovasculature, whereas J3T-2 and J3T-1shA tumors exhibited diffuse, infiltrative invasion without angiogenesis. Positive expression of annexin A2 was observed in tumor cells surrounding dilated vessels in 25/30 human glioblastoma specimens. Our results reveal that the phenotype of glioma invasion is closely related to angiogenesis. We identify annexin A2 as a factor regulating angiogenesis and invasion of malignant gliomas.

    DOI: 10.1007/s10014-015-0216-6

    Web of Science

    PubMed

    researchmap

  • Cdk5rap1-Mediated 2-Methylthio Modification of Mitochondrial tRNAs Governs Protein Translation and Contributes to Myopathy in Mice and Humans 査読 国際誌

    Fan-Yan Wei, Bo Zhou, Takeo Suzuki, Keishi Miyata, Yoshihiro Ujihara, Haruki Horiguchi, Nozomu Takahashi, Peiyu Xie, Hiroyuki Michiue, Atsushi Fujimura, Taku Kaitsuka, Hideki Matsui, Yasutoshi Koga, Satoshi Mohri, Tsutomu Suzuki, Yuichi Oike, Kazuhito Tomizawa

    CELL METABOLISM   21 ( 3 )   428 - 442   2015年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:CELL PRESS  

    Transfer RNAs (tRNAs) contain a wide variety of post-transcriptional modifications that are important for accurate decoding. Mammalian mitochondrial tRNAs (mt-tRNAs) are modified by nuclear-encoded tRNA-modifying enzymes; however, the physiological roles of these modifications remain largely unknown. In this study, we report that Cdk5 regulatory subunit-associated protein 1 (Cdk5rap1) is responsible for 2-methyl-thio (ms(2)) modifications of mammalian mt-tRNAs for Ser(UCN), Phe, Tyr, and Trp codons. Deficiency in ms(2) modification markedly impaired mitochondrial protein synthesis, which resulted in respiratory defects in Cdk5rap1 knockout (KO) mice. The KO mice were highly susceptive to stress-induced mitochondrial remodeling and exhibited accelerated myopathy and cardiac dysfunction under stressed conditions. Furthermore, we demonstrate that the ms(2) modifications of mt-tRNAs were sensitive to oxidative stress and were reduced in patients with mitochondrial disease. These findings highlight the fundamental role of ms(2) modifications of mt-tRNAs in mitochondrial protein synthesis and their pathological consequences in mitochondrial disease.

    DOI: 10.1016/j.cmet.2015.01.019

    Web of Science

    PubMed

    researchmap

  • A novel leucine zipper motif-based hybrid peptide delivers a functional peptide cargo inside cells. 査読 国際誌

    Y Hakata, S Tsuchiya, H Michiue, T Ohtsuki, H Matsui, M Miyazawa, M Kitamatsu

    Chemical communications (Cambridge, England)   51 ( 2 )   413 - 6   2015年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    A hybrid comprising an autophagy-inducing peptide (AIP) and a cell-penetrating peptide (CPP) connected via heterodimeric leucine zippers was generated and delivered into cells. The hybrid successfully induced autophagy without significant cell death, while the same AIP directly connected to a CPP caused both autophagy and significant cell death.

    DOI: 10.1039/c4cc07459a

    PubMed

    researchmap

  • Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma. 査読 国際誌

    Tomotsugu Ichikawa, Kazuhiko Kurozumi, Hiroyuki Michiue, Joji Ishida, Yoshinobu Maeda, Eisei Kondo, Akihiro Kawasaki, Isao Date

    Clinical neurology and neurosurgery   127   106 - 11   2014年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVE: Although high-dose methotrexate and whole-brain radiation therapy (WBRT) is the current standard for primary central nervous system lymphoma (PCNSL), it has a limited response rate and produces radiation-induced neurotoxicity. We report the effect of a combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) for immunocompetent patients with PCNSL. METHODS: We analyzed 24 patients who had received M-CHOP administered in 28-day cycles with or without WBRT. The response rate to M-CHOP, overall survival (OS), and recurrence-free survival (RFS) were analyzed. RESULTS: Nine patients were treated with M-CHOP plus WBRT and 15 patients were treated with M-CHOP alone. Twenty-one patients achieved a complete response and three patients achieved a partial response to M-CHOP, for a 100% response rate. With a median follow-up of 70 months, the median OS and RFS were 33 and 13 months, respectively. The median OS for patients treated with M-CHOP plus WBRT and M-CHOP alone was 33 and 32 months, respectively. Of the 13 patients whose age was above 65 years, the median OS for the M-CHOP plus WBRT group (two patients) and the M-CHOP alone group (11 patients) was 14 and 32 months, respectively. Toxicities related to M-CHOP were mostly hematologic and generally mild to moderate. Two patients whose age was above 65 years in the M-CHOP plus WBRT group developed neurotoxicity. CONCLUSION: Combined treatment with M-CHOP was well tolerated and produced a high response rate. Deferring WBRT was associated with reduced neurotoxicity without worsening the prognosis, especially in elderly patients.

    DOI: 10.1016/j.clineuro.2014.10.011

    PubMed

    researchmap

  • [The use of the ubiquitin-proteasome system in neurosurgery and the clinical applications of protein therapy]. 査読

    Hiroyuki Michiue, Isao Date

    No shinkei geka. Neurological surgery   42 ( 10 )   899 - 906   2014年10月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.11477/mf.1436200003

    PubMed

    researchmap

  • Methylphenidate improves learning impairments and hyperthermia-induced seizures caused by an Scn1a mutation 査読 国際誌

    Iori Ohmori, Nozomi Kawakami, Sumei Liu, Haijiao Wang, Ikuko Miyazaki, Masato Asanuma, Hiroyuki Michiue, Hideki Matsui, Tomoji Mashimo, Mamoru Ouchida

    EPILEPSIA   55 ( 10 )   1558 - 1567   2014年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-BLACKWELL  

    ObjectiveDevelopmental disorders including cognitive deficit, hyperkinetic disorder, and autistic behaviors are frequently comorbid in epileptic patients with SCN1A mutations. However, the mechanisms underlying these developmental disorders are poorly understood and treatments are currently unavailable. Using a rodent model with an Scn1a mutation, we aimed to elucidate the pathophysiologic basis and potential therapeutic treatments for developmental disorders stemming from Scn1a mutations.MethodsWe conducted behavioral analyses on rats with the N1417H-Scn1a mutation. With high-performance liquid chromatography, we measured dopamine and its metabolites in the frontal cortex, striatum, nucleus accumbens, and midbrain. Methylphenidate was administered intraperitoneally to examine its effects on developmental disorder-like behaviors and hyperthermia-induced seizures.ResultsBehavioral studies revealed that Scn1a-mutant rats had repetitive behavior, hyperactivity, anxiety-like behavior, spatial learning impairments, and motor imbalance. Dopamine levels in the striatum and nucleus accumbens in Scn1a-mutant rats were significantly lower than those in wild-type rats. In Scn1a-mutant rats, methylphenidate, by increasing dopamine levels in the synaptic cleft, improved hyperactivity, anxiety-like behavior, and spatial learning impairments. Surprisingly, methylphenidate also strongly suppressed hyperthermia-induced seizures.SignificanceDysfunction of the mesolimbic dopamine reward pathway may contribute to the hyperactivity and learning impairments in Scn1a-mutant rats. Methylphenidate was effective for treating hyperactivity, learning impairments, and hyperthermia-induced seizures. We propose that methylphenidate treatment may ameliorate not only developmental disorders but also epileptic seizures in patients with SCN1A mutations.

    DOI: 10.1111/epi.12750

    Web of Science

    PubMed

    researchmap

  • The transdermal inhibition of melanogenesis by a cell-membrane-permeable peptide delivery system based on poly-arginine 査読 国際誌

    Nanako Ookubo, Hiroyuki Michiue, Mizuki Kitamatsu, Maho Kamamura, Tei-ichi Nishiki, Iori Ohmori, Hideki Matsui

    BIOMATERIALS   35 ( 15 )   4508 - 4516   2014年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ELSEVIER SCI LTD  

    Topical therapy is the most favored form of treatment for whitening against hyper-pigmentation and sunburn because it lends itself to self-administration, patient compliance and an absence of systemic adverse effects. However, high-molecular-weight, hydrophilic chemicals are difficult to use as transdermal delivery drugs and the use of topical drugs has been highly limited. There are now many potent tyrosinase inhibitors, for example, sulfite or kojic acid, but the efficacy of their skin transduction remains a big problem. Furthermore, melanogenesis inhibitors from natural sources have great potential, as they are considered to be safe and largely free from adverse side effects. We applied 11-arginine (11R), a cell-membrane-permeable peptide, as a transdermal delivery system with a skin delivery enhancer, pyrenbutyrate. We performed intracellular screening for melanogenesis inhibitors with 11R fused with several kinds of tyrosinase inhibitory peptides from natural sources. Of 28 tyrosinase peptides, 13 melanin synthesis inhibitory peptides were selected. Peptide No. 10 found in gliadin protein, a wheat component, most strongly inhibited melanin production. This No. 10 peptide, of only 8 amino acids, fused to 11R showed no cytotoxicity and inhibited melanin synthesis as determined through melanin content measured using an absorption spectrometer and observation with a transmission electron microscope. Next, we transduced this 11R-No. 10 into skin with an 11R transdermal delivery system after previous treatment with pyrenbutyrate and performed daily repetitive topical application for two weeks against a UV-induced sun-tanning guinea pig model. We observed a whitening effect in a model skin sample by Masson-Fontana staining and the 11R-No. 10 peptide-applied area showed significant melanogenesis inhibition. These results show that 11R using a transdermal drug delivery system with melanogenesis inhibitory peptide is a very safe and promising method for applications from cosmetics to the pharmaceutical industry. (C) 2014 Elsevier Ltd. All rights reserved.

    DOI: 10.1016/j.biomaterials.2014.01.052

    Web of Science

    PubMed

    researchmap

  • The acceleration of boron neutron capture therapy using multi-linked mercaptoundecahydrododecaborate (BSH) fused cell-penetrating peptide. 査読 国際誌

    Hiroyuki Michiue, Yoshinori Sakurai, Natsuko Kondo, Mizuki Kitamatsu, Feng Bin, Kiichiro Nakajima, Yuki Hirota, Shinji Kawabata, Tei-ichi Nishiki, Iori Ohmori, Kazuhito Tomizawa, Shin-ichi Miyatake, Koji Ono, Hideki Matsui

    Biomaterials   35 ( 10 )   3396 - 405   2014年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    New anti-cancer therapy with boron neutron capture therapy (BNCT) is based on the nuclear reaction of boron-10 with neutron irradiation. The median survival of BNCT patients with glioblastoma was almost twice as long as those receiving standard therapy in a Japanese BNCT clinical trial. In this clinical trial, two boron compounds, BPA (boronophenylalanine) and BSH (sodium borocaptate), were used for BNCT. BPA is taken up into cells through amino acid transporters that are expressed highly in almost all malignant cells, but BSH cannot pass through the cell membrane and remains outside the cell. We simulated the energy transfer against the nucleus at different locations of boron from outside the cell to the nuclear region with neutron irradiation and concluded that there was a marked difference between inside and outside the cell in boron localization. To overcome this disadvantage of BSH in BNCT, we used a cell-penetrating peptide system for transduction of BSH. CPP (cell-membrane penetrating peptide) is very common peptide domains that transduce many physiologically active substances into cells in vitro and in vivo. BSH-fused CPPs can penetrate the cell membrane and localize inside a cell. To increase the boron ratio in one BSH-peptide molecule, 8BSH fused to 11R with a dendritic lysine structure was synthesized and administrated to malignant glioma cells and a brain tumor mouse model. 8BSH-11R localized at the cell nucleus and showed a very high boron value in ICP results. With neutron irradiation, the 8BSH-11R administrated group showed a significant cancer killing effect compared to the 100 times higher concentration of BSH-administrated group. We concluded that BSH-fused CPPs were one of the most improved and potential boron compounds in the next-stage BNCT trial and 8BSH-11R may be applied in the clinical setting.

    DOI: 10.1016/j.biomaterials.2013.12.055

    PubMed

    researchmap

  • Cyclin G2 promotes hypoxia-driven local invasion of glioblastoma by orchestrating cytoskeletal dynamics. 査読 国際誌

    Atsushi Fujimura, Hiroyuki Michiue, Yan Cheng, Atsuhito Uneda, Yasunari Tani, Tei-ichi Nishiki, Tomotsugu Ichikawa, Fan-Yan Wei, Kazuhito Tomizawa, Hideki Matsui

    Neoplasia (New York, N.Y.)   15 ( 11 )   1272 - 81   2013年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Microenvironmental conditions such as hypoxia potentiate the local invasion of malignant tumors including glioblastomas by modulating signal transduction and protein modification, yet the mechanism by which hypoxia controls cytoskeletal dynamics to promote the local invasion is not well defined. Here, we show that cyclin G2 plays pivotal roles in the cytoskeletal dynamics in hypoxia-driven invasion by glioblastoma cells. Cyclin G2 is a hypoxia-induced and cytoskeleton-associated protein and is required for glioblastoma expansion. Mechanistically, cyclin G2 recruits cortactin to the juxtamembrane through its SH3 domain-binding motif and consequently promotes the restricted tyrosine phosphorylation of cortactin in concert with src. Moreover, cyclin G2 interacts with filamentous actin to facilitate the formation of membrane ruffles. In primary glioblastoma, cyclin G2 is abundantly expressed in severely hypoxic regions such as pseudopalisades, which consist of actively migrating glioma cells. Furthermore, we show the effectiveness of dasatinib against hypoxia-driven, cyclin G2-involved invasion in vitro and in vivo. Our findings elucidate the mechanism of cytoskeletal regulation by which severe hypoxia promotes the local invasion and may provide a therapeutic target in glioblastoma.

    PubMed

    researchmap

  • Inhalation of 10% carbon dioxide rapidly terminates Scn1a mutation-related hyperthermia-induced seizures. 査読 国際誌

    Iori Ohmori, Keiichiro Hayashi, Haijiao Wang, Mamoru Ouchida, Naohiro Fujita, Takushi Inoue, Hiroyuki Michiue, Teiichi Nishiki, Hideki Matsui

    Epilepsy research   105 ( 1-2 )   220 - 4   2013年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The aim of this study was to assess the anticonvulsant effect of carbon dioxide (CO2) on Scn1a mutation-related febrile seizures. We examined physiological changes in the blood gas levels after the induction of hyperthermia-induced seizures (HISs), which were associated with the Scn1a missense mutation. We determined the efficacy of inhalation of 5% or 10% CO2 to treat HISs. HISs were evoked in Scn1a mutant and wild-type (WT) rats by hot water baths. To determine the anticonvulsant effect of CO2 inhalation, rats were placed in a chamber filled with air or mixed gas containing 5% CO2 or 10% CO2 for 3 min, immediately after the induction of HISs. We also analyzed the blood gas levels at the end of inhalation of CO2. Hot water bathing induced a significant reduction in the partial pressure of CO2 (pCO2) and respiratory alkalosis in the WT and Scn1a mutant rats. HISs were evoked in 100% of the Scn1a mutant rats within 5 min, but in none of the WT rats. The Scn1a mutant rats demonstrated a higher HISs susceptibility associated with respiratory alkalosis than the WT rats. Inhalation of 10% CO2 shortened the seizure duration from 62.6±12.1 s to 15.5±1.0 s. Blood gas analysis after the inhalation of 10% CO2 demonstrated an elevated pCO2 level and respiratory acidosis. Inhalation of 10% CO2 demonstrated a potent and fast-acting anticonvulsant effect against HISs.

    DOI: 10.1016/j.eplepsyres.2013.01.003

    PubMed

    researchmap

  • Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models 査読 国際誌

    Manabu Onishi, Tomotsugu Ichikawa, Kazuhiko Kurozumi, Kentaro Fujii, Koichi Yoshida, Satoshi Inoue, Hiroyuki Michiue, E. Antonio Chiocca, Balveen Kaur, Isao Date

    NEUROPATHOLOGY   33 ( 2 )   162 - 174   2013年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-BLACKWELL  

    Integrins are expressed in tumor cells and tumor endothelial cells, and likely play important roles in glioma angiogenesis and invasion. We investigated the anti-glioma mechanisms of cilengitide (EMD121974), an v3 integrin inhibitor, utilizing the novel invasive glioma models, J3T-1 and J3T-2. Immunohistochemical staining of cells in culture and brain tumors in rats revealed positive v3 integrin expression in J3T-2 cells and tumor endothelial cells, but not in J3T-1 cells. Established J3T-1 and J3T-2 orthotopic gliomas in athymic rats were treated with cilengitide or solvent. J3T-1 gliomas showed perivascular tumor cluster formation and angiogenesis, while J3T-2 gliomas showed diffuse single-cell infiltration without obvious angiogenesis. Cilengitide treatment resulted in a significantly decreased diameter of the J3T-1 tumor vessel clusters and its core vessels when compared with controls, while an anti-invasive effect was shown in the J3T-2 glioma with a significant reduction of diffuse cell infiltration around the tumor center. The survival of cilengitide-treated mice harboring J3T-1 tumors was significantly longer than that of control animals (median survival: 57.5 days and 31.8 days, respectively, P<0.005), while cilengitide had no effect on the survival of mice with J3T-2 tumors (median survival: 48.9 days and 48.5, P=0.69). Our results indicate that cilengitide exerts a phenotypic anti-tumor effect by inhibiting angiogenesis and glioma cell invasion. These two mechanisms are clearly shown by the experimental treatment of two different animal invasive glioma models.

    DOI: 10.1111/j.1440-1789.2012.01344.x

    Web of Science

    PubMed

    researchmap

  • CACNA1A variants may modify the epileptic phenotype of Dravet syndrome. 査読 国際誌

    Iori Ohmori, Mamoru Ouchida, Katsuhiro Kobayashi, Yoshimi Jitsumori, Akiko Mori, Hiroyuki Michiue, Teiichi Nishiki, Yoko Ohtsuka, Hideki Matsui

    Neurobiology of disease   50   209 - 17   2013年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Dravet syndrome is an intractable epileptic syndrome beginning in the first year of life. De novo mutations of SCN1A, which encode the Na(v)1.1 neuronal voltage-gated sodium channel, are considered the major cause of Dravet syndrome. In this study, we investigated genetic modifiers of this syndrome. We performed a mutational analysis of all coding exons of CACNA1A in 48 subjects with Dravet syndrome. To assess the effects of CACNA1A variants on the epileptic phenotypes of Dravet syndrome, we compared clinical features in two genotype groups: 1) subjects harboring SCN1A mutations but no CACNA1A variants (n=20) and 2) subjects with SCN1A mutations plus CACNA1A variants (n=20). CACNA1A variants detected in patients were studied using heterologous expression of recombinant human Ca(v)2.1 in HEK 293 cells and whole-cell patch-clamp recording. Nine CACNA1A variants, including six novel ones, were detected in 21 of the 48 subjects (43.8%). Based on the incidence of variants in healthy controls, most of the variants seemed to be common polymorphisms. However, the subjects harboring SCN1A mutations and CACNA1A variants had absence seizures more frequently than the patients with only SCN1A mutations (8/20 vs. 0/20, p=0.002). Moreover, the former group of subjects exhibited earlier onset of seizures and more frequent prolonged seizures before one year of age, compared to the latter group of subjects. The electrophysiological properties of four of the five novel Ca(v)2.1 variants exhibited biophysical changes consistent with gain-of-function. We conclude that CACNA1A variants in some persons with Dravet syndrome may modify the epileptic phenotypes.

    DOI: 10.1016/j.nbd.2012.10.016

    PubMed

    researchmap

  • 細胞膜透過ドメイン11Rを用いたHO-1蛋白の脳血管攣縮に対する効果

    小川 智之, 小野 成紀, Haenggi Daniel, 武 玉梅, 道上 宏之, 富澤 一仁, 松井 秀樹, Steiger Hans-Jakob, 伊達 勲

    脳血管攣縮   28   29 - 32   2013年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:スパズム・シンポジウム事務局  

    優れたタンパク質透過ドメインとして開発された「11R」を用い、脳血管拡張作用が報告されているHeme-oxygenase(HO)-1タンパクを融合させ、その有用性について検討した。まず11R-HO-1タンパク質の導入効率について、ラット大槽内より髄液を吸入した後に11R-HO-1タンパク質を注入し、免疫蛍光染色により脳底動脈の蛍光強度を測定した。その結果、注入2時間後には著明なHO-1タンパク質の発現を認め、発現は48時間以上持続し、高い導入効率が明らかとなった。次にラットクモ膜下出血モデルを用い、11R-HO-1タンパク質を注入して6時間後に血管径を測定したところ、HO-1注入群、11R注入群、11R-EGFP注入群に比較して脳底動脈径は有意に拡張しており、血管攣縮に対する効果が示された。

    researchmap

  • [Surgical and endovascular treatment for superior cerebellar artery aneurysms: report of two cases]. 査読

    Jun Haruma, Kenji Sugiu, Yosuke Shimazu, Hiroyuki Michiue, Koji Tokunaga, Isao Date

    No shinkei geka. Neurological surgery   41 ( 1 )   45 - 51   2013年1月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    Aneurysms located on the superior cerebellar artery (SCA) are uncommon and their presentation, natural history, and clinical management are poorly understood. Reports related to the endovascular or surgical management of SCA aneurysms are rare. Herein, we report two cases of SCA aneurysm. The first is that of a 70-year-old woman who presented with subarachnoid hemorrhage (SAH). Surgical treatment (neck clipping) of the ruptured SCA aneurysm was performed, and the flow of the parent artery disappeared. The second is that of a 69-year-old woman with an unruptured SCA aneurysm who underwent endovascular surgery to occlude the parent artery. Neither patients exhibited any additional neurological deficits. SCA aneurysms often have either relatively wide or undefinable necks, so it is difficult to preserve the parent artery. According to several surgical reports, occlusion of the SCA appears well tolerated for a variety of reasons.

    PubMed

    researchmap

  • Theranostic protein targeting ErbB2 for bioluminescence imaging and therapy for cancer. 査読 国際誌

    Xiao-Jian Han, Ling-Fei Sun, Yuki Nishiyama, Bin Feng, Hiroyuki Michiue, Masaharu Seno, Hideki Matsui, Kazuhito Tomizawa

    PloS one   8 ( 9 )   e75288   2013年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    A combination of molecular-targeted cancer imaging and therapy is an emerging strategy to improve cancer diagnosis and minimize the side effects of conventional treatments. Here, we generated a recombinant protein, EC1-GLuc-p53C, by fusing EC1 peptide, an artificial ligand of ErbB2, with Gaussia luciferase (GLuc) and a p53-activating peptide, p53C. EC1-GLuc-p53C was expressed and purified from E. coli BL21. In vitro experiments showed that EC1-GLuc-p53c was stable in luminescent activity and selectively targeted ErbB2-overexpressing BT474 cells for bioluminescence imaging. Moreover, the internalized EC1-GLuc-p53C in BT474 cells exerted its function to reactivate p53 and significantly inhibited cellular proliferation. In tumor-bearing mice, the ErbB2-targeted bioluminescence imaging and therapeutic effect of EC1-GLuc-p53C were also observed specifically in BT474 tumors but not in MCF7 tumors, which does not overexpress ErbB2. Thus, the present study demonstrates EC1-GLuc-p53C to be an effective theranostic reagent targeting ErbB2 for bioluminescence imaging and cancer therapy.

    DOI: 10.1371/journal.pone.0075288

    PubMed

    researchmap

  • Gene expression profiling of the anti-glioma effect of Cilengitide 査読 国際誌

    Manabu Onishi, Kazuhiko Kurozumi, Tomotsugu Ichikawa, Hiroyuki Michiue, Kentaro Fujii, Joji Ishida, Yosuke Shimazu, E. Antonio Chiocca, Balveen Kaur, Isao Date

    SPRINGERPLUS   2 ( 1 )   160 - 160   2013年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPRINGER INTERNATIONAL PUBLISHING AG  

    Cilengitide (EMD121974), an inhibitor of the adhesive function of integrins, demonstrated preclinical efficacy against malignant glioma. It is speculated that cilengitide can inhibit tumor growth, invasion, and angiogenesis. However, the effects of cilengitide on these processes have not been sufficiently examined. In this study, we investigated the anti-glioma effect of cilengitide using DNA microarray analysis. U87 Delta EGFR cells (human malignant glioma cell line) were used for this experiment. The cells were harvested after 16 h of cilengitide treatment, and mRNA was extracted. Gene expression and pathway analyses were performed using a DNA microarray (CodeLink (TM) Human Whole Genome Bioarray). The expression of 265 genes was changed with cilengitide treatment. The expression of 214 genes was up-regulated by more than 4-fold and the expression of 51 genes was down-regulated by more than 4-fold compared to the controls. In pathway analysis, "apoptotic cleavage of cellular proteins" and "TNF receptor signaling pathway" were over-represented. Apoptotic-associated genes such as caspase 8 were up-regulated. Gene expression profiling revealed more detailed mechanism of the anti-glioma effect of cilengitide. Genes associated with apoptosis were over-represented following cilengitide treatment.

    DOI: 10.1186/2193-1801-2-160

    Web of Science

    PubMed

    researchmap

  • Induction of autophagic cell death of glioma-initiating cells by cell-penetrating D-isomer peptides consisting of Pas and the p53 C-terminus 査読 国際誌

    Yutaka Ueda, Fan-Yan Wei, Taku-ichiro Hide, Hiroyuki Michiue, Kentaro Takayama, Taku Kaitsuka, Hideo Nakamura, Keishi Makino, Jun-ichi Kuratsu, Shiroh Futaki, Kazuhito Tomizawa

    BIOMATERIALS   33 ( 35 )   9061 - 9069   2012年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ELSEVIER SCI LTD  

    Glioblastoma multiforme (GBM) is the most aggressive and fatal brain tumor. GBM is resistant to chemotherapy and radiation. Recent studies have shown that glioma-initiating cells (GICs), which have characteristics of cancer stem cells, are responsible for the resistance to chemotherapy and radiation and regrowth. No effective therapy for GICs has been developed. Here we showed that D-isomer peptides (dPasFHV-p53C') consisting of a cell-penetrating peptide (FHV), penetration accelerating sequence (Pas) and C-terminus of p53 (p53C') induced the cell death of GICs. dPasFHV-p53C' was effectively transduced into human GICs. The peptides dose-dependently inhibited cell growth and at 3 mu M completely blocked the growth of GICs but not embryonic stem cells. Autophagic cell death was observed in the GICs treated with dPasFHV-p53C' but apoptosis was not. dPasFHV without p53C' showed the same effect as dPasFHV-p53C', suggesting Pas to play a critical role in the cell death of GICs. Finally, dPasFHV-p53C' reduced tumor mass in mice transplanted with GICs. Peptide transduction therapy using dPasFHV-p53C' could be a new method for the treatment of GBM. (C) 2012 Elsevier Ltd. All rights reserved.

    DOI: 10.1016/j.biomaterials.2012.09.003

    Web of Science

    PubMed

    researchmap

  • Combining poly-arginine with the hydrophobic counter-anion 4-(1-pyrenyl)-butyric acid for protein transduction in transdermal delivery. 査読 国際誌

    Gerile Candan, Hiroyuki Michiue, Sanae Ishikawa, Atsushi Fujimura, Keiichiro Hayashi, Atsuhito Uneda, Akiko Mori, Iori Ohmori, Tei-ichi Nishiki, Hideki Matsui, Kazuhito Tomizawa

    Biomaterials   33 ( 27 )   6468 - 75   2012年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Topical therapy is the most favored form of treatment for whitening against hyperpigmentation and sunburn because it lends itself to self-administration, patient compliance, and absence of systemic adverse effects. However, transdermal delivery of hydrophilic chemicals is difficult. The main purpose of this study is to develop a delivering system of hydrophilic drugs and proteins across the skin. Hydroquinone (HQ), a well-known tyrosinase inhibitor and antimelanogenesis compound, and enhanced green fluorescent protein (EGFP) were fused with eleven poly-arginine (11R). Both HQ-11R and EGFP-11R were efficiently delivered in B16 cells, a mouse melanoma cell line. HQ-11R was as effective as HQ alone at inhibiting melanin synthesis in B16 cells. EGFP-11R was efficiently delivered into cells of the epidermis with 4-(1-pyrenyl)-butyric acid (PB), a counteranion bearing an aromatic hydrophobic moiety, in vivo, but EGFP alone or EGFP-11R without PB was not. Finally, topical application of HQ-11R with PB significantly inhibited UV irradiation-induced pigmentation in guinea pigs compared with HQ alone. These results suggest that topical therapy using poly-arginine in combination with PB is useful for the delivery of hydrophilic drugs and proteins by the transdermal route.

    DOI: 10.1016/j.biomaterials.2012.04.056

    PubMed

    researchmap

  • A protein transduction method using oligo-arginine (3R) for the delivery of transcription factors into cell nuclei. 査読 国際誌

    Takashi Hitsuda, Hiroyuki Michiue, Mizuki Kitamatsu, Atsushi Fujimura, Feifei Wang, Takahiro Yamamoto, Xiao-Jian Han, Hiroshi Tazawa, Atsuhito Uneda, Iori Ohmori, Tei-ichi Nishiki, Kazuhito Tomizawa, Hideki Matsui

    Biomaterials   33 ( 18 )   4665 - 72   2012年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Protein transduction with cell-penetrating peptides such as poly-arginine and HIV TAT peptides is widely used to deliver proteins, peptides, siRNA and biologically active compounds. It has been thought that poly-arginine peptides transduce proteins in a manner dependent on the number of arginine residues and oligo-peptides such as three arginines (3R) are ineffective. Here we showed that 3R-fused proteins were effectively delivered and functioned in cells co-treated with pyrenebutyrate, a counteranion bearing an aromatic hydrophobic moiety. Little 3R was transduced in glioma cells without pyrenebutyrate whereas the oligo-arginine was effectively delivered with pyrenebutyrate. Enhanced green fluorescence protein (eGFP) fused with 3R was effectively delivered into various kinds of cells including primary cultured cells and suspended cells in the presence of pyrenebutyrate. p53 fused with 3R (3R-p53) was delivered into glioma cells without pyrenebutyrate but could not be translocated into the nucleus. In contrast, 3R-p53 was observed in nuclei of glioma cells when co-applied with pyrenebutyrate. Although 3R-p53 was delivered less effectively than 11R-p53 with pyrenebutyrate, its transcriptional activity was higher than that of 11R-p53. Moreover, a single administration of 3R-p53 with pyrenebutyrate significantly inhibited the growth of cancer cells. These results suggest protein transduction using an oligo-arginine (3R) with pyrenebutyrate to be a good tool for the delivery of functional transcription factors and a promising method of treating cancer.

    DOI: 10.1016/j.biomaterials.2012.02.049

    PubMed

    researchmap

  • オキシトシンの抗うつ作用に関わるマウス海馬神経細胞内シグナル伝達経路

    松崎 光博, 松下 博昭, 韓 小建, 沖本 直輝, 道上 宏之, 西木 禎一, 大守 伊織, 富澤 一仁, 松井 秀樹

    日本生理学雑誌   74 ( 2 )   46 - 46   2012年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本生理学会  

    researchmap

  • Antidepressant-like effect of sildenafil through oxytocin-dependent cyclic AMP response element-binding protein phosphorylation. 査読 国際誌

    H Matsushita, M Matsuzaki, X-J Han, T-I Nishiki, I Ohmori, H Michiue, H Matsui, K Tomizawa

    Neuroscience   200   13 - 8   2012年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Oxytocin (OT) levels in plasma increase during sexual response and are significantly lower in patients with depression. A drug for the treatment of sexual dysfunction, sildenafil, enhances the electrically evoked release of OT from the posterior pituitary. In this study, we showed that sildenafil had an antidepressant-like effect through activation of an OT signaling pathway. Application of sildenafil reduced depression-related behavior in male mice. The antidepressant-like effect was blocked by an OT receptor (OTR) antagonist and was absent in OTR knockout (KO) mice. Sildenafil increased the phosphorylation of cAMP response element-binding protein (CREB) in the hippocampus. The OTR antagonist inhibited sildenafil-induced CREB phosphorylation and sildenafil had no effect on CREB phosphorylation in OTR KO mice. These results suggest sildenafil to have an antidepressant-like effect through the activation of OT signaling and to be a promising drug for the treatment of depression.

    DOI: 10.1016/j.neuroscience.2011.11.001

    PubMed

    researchmap

  • Ca(2+)-independent syntaxin binding to the C(2)B effector region of synaptotagmin. 査読 国際誌

    Toshio Masumoto, Koichiro Suzuki, Iori Ohmori, Hiroyuki Michiue, Kazuhito Tomizawa, Atsushi Fujimura, Tei-ichi Nishiki, Hideki Matsui

    Molecular and cellular neurosciences   49 ( 1 )   1 - 8   2012年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Although synaptotagmin I, which is a calcium (Ca(2+))-binding synaptic vesicle protein, may trigger soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE)-mediated synaptic vesicle exocytosis, the mechanisms underlying the interaction between these proteins remain controversial, especially with respect to the identity of the protein(s) in the SNARE complex that bind(s) to synaptotagmin and whether Ca(2+) is required for their highly effective binding. To address these questions, native proteins were solubilized, immunoprecipitated from rat brain extracts, and analyzed by immunoblotting. SNARE complexes comprising syntaxin 1, 25-kDa synaptosomal-associated protein (SNAP-25), and synaptobrevin 2 were coprecipitated with synaptotagmin I in the presence of ethylene glycol tetraacetic acid. The amount of coprecipitated proteins was significantly unaltered by the addition of Ca(2+) to the brain extract. To identify the component of the SNARE complex that bound to synaptotagmin, SNARE was coexpressed with synaptotagmin in HEK293 cells and immunoprecipitated. Syntaxin, but not SNAP-25 and synaptobrevin, bound to synaptotagmin in a Ca(2+)-independent manner, and the binding was abolished in the presence of 1M NaCl. Synaptotagmin contains 2 Ca(2+)-binding domains (C(2)A, C(2)B). Mutating the positively charged lysine residues in the putative effector-binding region of the C(2)B domain, which are critical for transmitter release, markedly inhibited synaptotagmin-syntaxin binding, while similar mutations in the C(2)A domain had no effect on binding. Synaptotagmin-syntaxin binding was reduced by mutating multiple negatively charged glutamate residues in the amino-terminal half of the syntaxin SNARE motif. These results indicate that synaptotagmin I binds to syntaxin 1 electrostatically through its C(2)B domain effector region in a Ca(2+)-independent fashion, providing biochemical evidence that synaptotagmin I binds SNARE complexes before Ca(2+) influx into presynaptic nerve terminals.

    DOI: 10.1016/j.mcn.2011.09.007

    PubMed

    researchmap

  • Protein therapy using heme-oxygenase-1 fused to a polyarginine transduction domain attenuates cerebral vasospasm after experimental subarachnoid hemorrhage. 査読 国際誌

    Tomoyuki Ogawa, Daniel Hänggi, Yumei Wu, Hiroyuki Michiue, Kazuhito Tomizawa, Shigeki Ono, Hideki Matsui, Isao Date, Hans-Jakob Steiger

    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism   31 ( 11 )   2231 - 42   2011年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    A sequence of 11 consecutive arginine residues (11R) is one of the best protein transduction domains for introducing proteins into cell membranes. Heme-oxygenase-1 (HO-1) is involved in heme catabolism and reduces the contractile effect of hemoglobin after subarachnoid hemorrhage (SAH). Therefore, we constructed 11R-fused HO-1 protein to achieve successful transduction of the protein into the cerebral arteries and examined the therapeutic effect of the 11R-HO-1 protein for cerebral vasospasm (CV) after SAH. We injected the 11R-HO-1 protein into the cisterna magna of male rats and, several hours after the injection, performed immunofluorescence staining and western blotting analysis of the rat basilar arteries (BAs) to determine transduction efficacy. We also assessed intraarterial HO-1 activity as cGMP (cyclic guanosine 3', 5'-cyclic monophosphate) accumulation in SAH and determined whether protein transduction of 11R-HO-1 quantified the therapeutic effect in a rat double-hemorrhage model of SAH. The BAs expressed significantly more HO-1 in the group injected with 11R-HO-1 (3.56±0.54 (11R-HO-1) versus control (saline)), and transduction of 11R-HO-1 resulted in higher activity (>3.25-fold) in rat BAs with SAH. Moreover, the results of the rat double-hemorrhage model showed that the 11R-HO-1 protein significantly attenuated CV after SAH (317.59±23.48 μm (11R-HO-1) versus 270.08±14.66 μm (11R-fused enhanced green fluorescent protein), 252.05±13.95 μm (saline), P<0.01).

    DOI: 10.1038/jcbfm.2011.87

    PubMed

    researchmap

  • Deficit of tRNA(Lys) modification by Cdkal1 causes the development of type 2 diabetes in mice 査読 国際誌

    Fan-Yan Wei, Takeo Suzuki, Sayaka Watanabe, Satoshi Kimura, Taku Kaitsuka, Atsushi Fujimura, Hideki Matsui, Mohamed Atta, Hiroyuki Michiue, Marc Fontecave, Kazuya Yamagata, Tsutomu Suzuki, Kazuhito Tomizawa

    JOURNAL OF CLINICAL INVESTIGATION   121 ( 9 )   3598 - 3608   2011年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:AMER SOC CLINICAL INVESTIGATION INC  

    The worldwide prevalence of type 2 diabetes (T2D), which is caused by a combination of environmental and genetic factors, is increasing. With regard to genetic factors, variations in the gene encoding Cdk5 regulatory associated protein 1-like 1 (Cdkal1) have been associated with an impaired insulin response and increased risk of T2D across different ethnic populations, but the molecular function of this protein has not been characterized. Here, we show that Cdkal1 is a mammalian methylthiotransferase that biosynthesizes 2-methylthio-N-6-threonylcarbamoyladenosine (ms(2)t(6)A) in tRNA(Lys)(UUU) and that it is required for the accurate translation of AAA and AAG codons. Mice with pancreatic beta cell-specific KO of Cdkal1 (referred to herein as beta cell KO mice) showed pancreatic islet hypertrophy, a decrease in insulin secretion, and impaired blood glucose control. In Cdkal1-deficient beta cells, misreading of Lys codon in proinsulin Occurred, resulting in a reduction of glucose-stimulated proinsulin synthesis. Moreover, expression of ER stress-related genes was upregulated in these cells, and abnormally structured ER was observed. Further, the beta cell KO mice were hypersensitive to high fat diet-induced ER stress. These findings suggest that glucose-stimulated translation of proinsulin may require fully modified tRNA(Lys)(UUU), which could potentially explain the molecular pathogenesis of T2D in patients carrying cdkal1 risk alleles.

    DOI: 10.1172/JCI58056

    Web of Science

    PubMed

    researchmap

  • Expression of a constitutively active calcineurin encoded by an intron-retaining mRNA in follicular keratinocytes. 査読 国際誌

    Atsushi Fujimura, Hiroyuki Michiue, Tei-ichi Nishiki, Iori Ohmori, Fan-Yan Wei, Hideki Matsui, Kazuhito Tomizawa

    PloS one   6 ( 3 )   e17685   2011年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Hair growth is a highly regulated cyclical process. Immunosuppressive immunophilin ligands such as cyclosporin A (CsA) and FK506 are known as potent hair growth modulatory agents in rodents and humans that induce active hair growth and inhibit hair follicle regression. The immunosuppressive effectiveness of these drugs has been generally attributed to inhibition of T cell activation through well-characterized pathways. Specifically, CsA and FK506 bind to intracellular proteins, principally cyclophilin A and FKBP12, respectively, and thereby inhibit the phosphatase calcineurin (Cn). The calcineurin (Cn)/NFAT pathway has an important, but poorly understood, role in the regulation of hair follicle development. Here we show that a novel-splicing variant of calcineurin Aß CnAß-FK, which is encoded by an intron-retaining mRNA and is deficient in the autoinhibitory domain, is predominantly expressed in mature follicular keratinocytes but not in the proliferating keratinocytes of rodents. CnAß-FK was weakly sensitive to Ca(2+) and dephosphorylated NFATc2 under low Ca(2+) levels in keratinocytes. Inhibition of Cn/NFAT induced hair growth in nude mice. Cyclin G2 was identified as a novel target of the Cn/NFATc2 pathway and its expression in follicular keratinocytes was reduced by inhibition of Cn/NFAT. Overexpression of cyclin G2 arrested the cell cycle in follicular keratinocytes in vitro and the Cn inhibitor, cyclosporin A, inhibited nuclear localization of NFATc2, resulting in decreased cyclin G2 expression in follicular keratinocytes of rats in vivo. We therefore suggest that the calcineurin/NFAT pathway has a unique regulatory role in hair follicle development.

    DOI: 10.1371/journal.pone.0017685

    PubMed

    researchmap

  • Transdifferentiation of glioblastoma cells into vascular endothelial cells 査読 国際誌

    Yasushi Soda, Tomotoshi Marumoto, Dinorah Friedmann-Morvinski, Mie Soda, Fei Liu, Hiroyuki Michiue, Sandra Pastorino, Meng Yang, Robert M. Hoffman, Santosh Kesari, Inder M. Verma

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA   108 ( 11 )   4274 - 4280   2011年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:NATL ACAD SCIENCES  

    Glioblastoma (GBM) is the most malignant brain tumor and is highly resistant to intensive combination therapies and anti-VEGF therapies. To assess the resistance mechanism to anti-VEGF therapy, we examined the vessels of GBMs in tumors that were induced by the transduction of p53(+/-) heterozygous mice with lentiviral vectors containing oncogenes and the marker GFP in the hippocampus of GFAP-Cre recombinase (Cre) mice. We were surprised to observe GFP(+) vascular endothelial cells (ECs). Transplantation of mouse GBM cells revealed that the tumor-derived endothelial cells (TDECs) originated from tumor-initiating cells and did not result from cell fusion of ECs and tumor cells. An in vitro differentiation assay suggested that hypoxia is an important factor in the differentiation of tumor cells to ECs and is independent of VEGF. TDEC formation was not only resistant to an anti-VEGF receptor inhibitor in mouse GBMs but it led to an increase in their frequency. A xenograft model of human GBM spheres from clinical specimens and direct clinical samples from patients with GBM also showed the presence of TDECs. We suggest that the TDEC is an important player in the resistance to anti-VEGF therapy, and hence a potential target for GBM therapy.

    DOI: 10.1073/pnas.1016030108

    Web of Science

    PubMed

    researchmap

  • Poly-arginine domainによる細胞内導入効率と細胞制御について

    櫃田 隆, 道上 宏之, 山口 晃正, 藤村 篤史, 富澤 一仁, 松井 秀樹

    日本生理学雑誌   73 ( 2 )   36 - 36   2011年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本生理学会  

    researchmap

  • Ca2+-dependent dissociation of synaptotagmin I from SNARE complexes 査読

    Koichiro Suzuki, Toshio Masumoto, Iori Ohmori, Hiroyuki Michiue, Tei-ichi Nishiki, Hideki Matsui

    NEUROSCIENCE RESEARCH   71   E314 - E314   2011年

     詳細を見る

    記述言語:英語   出版者・発行元:ELSEVIER IRELAND LTD  

    DOI: 10.1016/j.neures.2011.07.1372

    Web of Science

    researchmap

  • The neuroprotective effects of GDNF-pretreatment for neural stem cell transplantation in the 6-OHDA-lesioned rats 査読

    Feifei Wang, Hiroyuki Michiue, Masahiro Kameda, Teiichi Nishiki, Iori Ohmori, Isao Date, Hideki Matsui

    NEUROSCIENCE RESEARCH   71   E137 - E138   2011年

     詳細を見る

    記述言語:英語   出版者・発行元:ELSEVIER IRELAND LTD  

    DOI: 10.1016/j.neures.2011.07.592

    Web of Science

    researchmap

  • 脳腫瘍治療の新潮流(転移性脳腫瘍を含む) 膠芽腫に対するホウ素中性子捕捉療法、X線外照射、化学療法 第II相臨床試験の近況

    川端 信司, 宮武 伸一, 平松 亮, 宮田 至朗, 嶽北 葉子, 黒岩 敏彦, 道上 宏之, 小野 公二

    日本癌治療学会誌   45 ( 2 )   384 - 384   2010年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本癌治療学会  

    researchmap

  • Development of a bifunctional immunoliposome system for combined drug delivery and imaging in vivo. 査読 国際誌

    Bin Feng, Kazuhito Tomizawa, Hiroyuki Michiue, Xiao-Jian Han, Shin-ichi Miyatake, Hideki Matsui

    Biomaterials   31 ( 14 )   4139 - 45   2010年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The diverse characteristics of immunoliposomes provide advantages for utilization in drug delivery systems. In this study, we fused the antibody affinity motif of protein A (ZZ) with Gaussia luciferase (GLase). The fused protein conjugated with an anti-epidermal growth factor receptor (EGFR) monoclonal antibody (GLase-ZZ-His-mAb) was effectively delivered into glioma cells expressing an activated EGFR mutant (EGFRvIII) and the bioluminescence was visualized in the cells. Immunoliposomes were further constructed with DSPE-PEG-MAL for covalent GLase-ZZ-His-mAb conjugation. A fluorescence dye (HPTS) encapsulated in immunoliposomes conjugated with GLase-ZZ-His-mAb was effectively delivered into EGFRvIII-expressing glioma cells. In a murine xenograft model of glioma, moreover, specific targeting of the immunoliposomes was visualized in the tumor. This new bifunctional immunoliposome system has the potential for drug delivery and imaging in vivo.

    DOI: 10.1016/j.biomaterials.2010.01.086

    PubMed

    researchmap

  • Development of a new theranostics for ErbB 2-overexpressing cancer 査読

    Lingfei Sun, Xiao-Jian Han, Yuki Nishiyama, Hiroyuki Michiue, Kazuhito Tomizawa, Hideki Matsui

    JOURNAL OF PHYSIOLOGICAL SCIENCES   60   S108 - S108   2010年

     詳細を見る

    記述言語:英語   出版者・発行元:SPRINGER TOKYO  

    Web of Science

    researchmap

  • Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma. 査読 国際誌

    Hiroyuki Michiue, Akiko Eguchi, Miriam Scadeng, Steven F Dowdy

    Cancer biology & therapy   8 ( 23 )   2306 - 13   2009年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Glioblastoma multiforme remains one of the most intractable human malignancies. Glioblastomas arise due to activation of multiple oncogenic pathways leading to increased cellular growth, proliferation and tumor cell survival. siRNA induced RNA Interference (RNAi) responses result in the degradation of specific mRNA species. In theory, RNAi responses can selectively target intersecting oncogenic pathways to induce a tumor cell specific RNAi synthetic lethal response. However, the concept of inducing in vivo synthetic lethal RNAi responses has not yet been addressed. Here we tested the in vivo ability of synthetic lethal RNAi responses to treat glioblastoma. To deliver siRNAs into cells, we fused a peptide transduction delivery domain to a dsRNA-binding domain (PTD-DRBD). DRBDs avidly bind to siRNAs, masking the siRNA anionic negative charge and allowing for efficient PTD-mediated siRNA delivery into the entire cell population. Combinatorial targeting of EGF-Receptor (EGFR) and Akt2, but not Ak1 or Akt3, by PTD-DRBD delivered siRNAs synergized to induce tumor cell specific apoptosis. In vivo PTD-DRBD delivery of EGFR and Akt2 siRNAs induced tumor specific apoptosis and significantly increased survival in intracerebral glioblastoma mouse models (p < 0.0005), whereas delivery of irrelevant control siRNAs did not alter longevity. Thus, siRNA induced synthetic lethal RNAi responses have great potential for personalized medicine treatment of cancer.

    PubMed

    researchmap

  • Enhanced intracellular delivery using arginine-rich peptides by the addition of penetration accelerating sequences (Pas) 査読 国際誌

    Kentaro Takayama, Ikuhiko Nakase, Hiroyuki Michiue, Toshihide Takeuchi, Kazuhito Tomizawa, Hideki Matsui, Shiroh Futaki

    JOURNAL OF CONTROLLED RELEASE   138 ( 2 )   128 - 133   2009年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ELSEVIER SCIENCE BV  

    Cell penetrating peptides (CPPs), including arginine-rich peptides, are attractive tools for the intracellular delivery of various bioactive molecules with a low membrane permeability. We showed that the accelerated intracellular delivery of arginine-rich peptides was achieved by the addition of a short peptide segment (penetration accelerating sequence, Pas) to arginine-rich CPPs. The cytosolic release of the Pas-attached arginine-rich CPPs was observed within 5 min after the treatment of the cells with the peptides even in the presence of serum. Effectiveness of the Pas segment in the intracellular delivery of bioactive peptides using arginine-rich CPPs was exemplified through the enhanced growth inhibition activity of the malignant glioma cells by a retro-inverso peptide derived from the p53 C-terminal 22-amino-acid segment (positions 361-382). All rights reserved. (C) 2009 Elsevier B.V. All rights reserved.

    DOI: 10.1016/j.jconrel.2009.05.019

    Web of Science

    PubMed

    researchmap

  • Survival benefit from boron neutron capture therapy for the newly diagnosed glioblastoma patients. 査読 国際誌

    Shinji Kawabata, Shin-Ichi Miyatake, Naosuke Nonoguchi, Ry Hiramatsu, Kyoko Iida, Shiro Miyata, Kunio Yokoyama, Atsushi Doi, Yuzo Kuroda, Toshihiko Kuroiwa, Hiroyuki Michiue, Hiroaki Kumada, Mitsunori Kirihata, Yoshio Imahori, Akira Maruhashi, Yoshinori Sakurai, Minoru Suzuki, Shin-Ichiro Masunaga, Koji Ono

    Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine   67 ( 7-8 Suppl )   S15-8   2009年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVE: Since 2002-2007, we applied boron neutron capture therapy (BNCT) to >50 cases of malignant gliomas (MGs) with epithermal neutron irradiations. Recently, we showed the early radiographical improvement of malignant glioma patients by our modified BNCT, with simultaneous use of BPA (borono-phenylalanine) and BSH (sodium borocaptate). In this time, we focused on the survival benefit from BNCT for the newly diagnosed glioblastoma patients. METHODS: BNCT group including 21 newly histological confirmed glioblastoma patients treated with surgical removal followed by BNCT in Osaka Medical College during 2002-2006 period. Ten patients were treated with BNCT only, and in the other 11 patients, 20-30 Gy fractionated external beam X-ray irradiation therapy (XRT) was performed after BNCT. No chemotherapy was administered until tumor progression was observed. RESULTS: Treatments were well tolerated. Any kind of acute systemic or local severe toxicity were not demonstrated. Mean over all survival of the patients treated by BNCT was 20.7 and the median was 15.6 months with 2-years survival of 25%. Stratification by RPA criteria showed 6, 6, 8 and 1 patients, respectively, in classes III-VI. Three patients out of six in class III and one out of eight in class V are alive at the end point of this study. All the patients in classes IV and VI died. Median survival time for the BNCT group compared to the RTOG database was as follows: 20.6 months vs. 17.9 months for class III; 16.9 months vs. 11.1 months for class IV; 13.2 months vs. 8.9 months for class V. CONCLUSION: The RTOG RPA prognostic criteria were helpful in establishing which class of glioma patients could potentially benefit from BNCT. BNCT showed a survival benefit in all of the RPA classes of the RTOG database not only for the good prognosis group.

    DOI: 10.1016/j.apradiso.2009.03.015

    PubMed

    researchmap

  • Survival benefit of boron neutron capture therapy for recurrent malignant gliomas. 査読 国際誌

    Shin-Ichi Miyatake, Shinji Kawabata, Kunio Yokoyama, Toshihiko Kuroiwa, Hiroyuki Michiue, Yoshinori Sakurai, Hiroaki Kumada, Minoru Suzuki, Akira Maruhashi, Mitsunori Kirihata, Koji Onoc

    Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine   67 ( 7-8 Suppl )   S22-4   2009年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    We have applied boron neutron capture therapy (BNCT) to malignant brain tumors. Here we evaluated the survival benefit of BNCT for recurrent malignant glioma (MG). Since 2002, we have treated 22 cases of recurrent MG with BNCT. Survival time was analyzed with special reference to recursive partitioning analysis (RPA) classification, by Carson et al. Median survival times (MSTs) after BNCT for all patients and for glioblastoma as on-study histology at recurrence was 10.8 months (n=22; 95% CI, 7.3-12.8 months) and 9.6 months (n=19; 95% CI, 6.9-11.4 months), respectively. In our study, MST for the high-risk RPA classes was 9.1 months (n=11; 95% CI, 4.4-11.0 months). By contrast, the original journal data showed that the MST of the same RPA classes was 4.4 months (n=129; 95% CI, 3.6-5.4 months). BNCT showed a survival benefit for recurrent MG, especially in the high-risk group.

    DOI: 10.1016/j.apradiso.2009.03.032

    PubMed

    researchmap

  • Delivery of sodium borocaptate to glioma cells using immunoliposome conjugated with anti-EGFR antibodies by ZZ-His. 査読 国際誌

    Bin Feng, Kazuhito Tomizawa, Hiroyuki Michiue, Shin-ichi Miyatake, Xiao-Jian Han, Atsushi Fujimura, Masaharu Seno, Mitsunori Kirihata, Hideki Matsui

    Biomaterials   30 ( 9 )   1746 - 55   2009年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Nanoparticles are effective of delivering cargo into cells. Here, sodium borocaptate (BSH) was encapsulated in liposomes composed of nickel lipid, and anti-epidermal growth factor receptor (EGFR) antibodies were conjugated to the liposomes using the antibody affinity motif of protein A (ZZ) as an adaptor (immunoliposomes). The immunoliposomes were used to deliver BSH into EGFR-overexpressing glioma cells. Immunohistochemical analysis using an anti-BSH monoclonal antibody revealed that BSH was delivered effectively into the cells but not into EGFR-deficient glioma or primary astrocytes. In an animal model of brain tumors, both the liposomes and the BSH were only observed in the tumor. Moreover, the efficiency of (10)B's delivery into glioma cells was confirmed by inductively coupled plasma-atomic emission spectrometry (ICP-AES) both in vitro and in vivo. The results suggest that this system utilizing immunoliposomes provides an effective means of delivering (10)B into glioma cells in boron neutron capture therapy (BNCT).

    DOI: 10.1016/j.biomaterials.2008.12.010

    PubMed

    researchmap

  • Protein Transduction therapyを用いた新規siRNA導入システムの開発

    道上 宏之, 黒住 和彦, 市川 智継, Dowdy S., 伊達 勲, 松井 秀樹, 富澤 一仁

    日本生理学雑誌   71 ( 3 )   151 - 151   2009年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本生理学会  

    researchmap

  • Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas. 査読 国際誌

    Shin-Ichi Miyatake, Shinji Kawabata, Kunio Yokoyama, Toshihiko Kuroiwa, Hiroyuki Michiue, Yoshinori Sakurai, Hiroaki Kumada, Minoru Suzuki, Akira Maruhashi, Mitsunori Kirihata, Koji Ono

    Journal of neuro-oncology   91 ( 2 )   199 - 206   2009年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    We have applied boron neutron capture therapy (BNCT) to malignant brain tumors. Here we evaluated the survival benefit of BNCT for recurrent malignant glioma (MG). Since 2002, we have treated 22 cases of recurrent MG with BNCT. Survival time was analyzed with special reference to recursive partitioning analysis (RPA) classification, by Carson et al. (J Clin Oncol 25:2601-2606, 2007). Median survival times (MSTs) after BNCT for all patients and for glioblastoma as on-study histology at recurrence was 10.8 months (n = 22; 95% CI, 7.3-12.8 months) and 9.6 months (n = 19; 95% CI, 6.9-11.4 months), respectively. In our study, MST for the high-risk RPA classes was 9.1 months (n = 11; 95% CI, 4.4-11.0 months). By contrast, the original journal data showed that the MST of the same RPA classes was 4.4 months (n = 129; 95% CI, 3.6-5.4 months). BNCT showed a survival benefit for recurrent MG, especially in the high-risk group.

    DOI: 10.1007/s11060-008-9699-x

    PubMed

    researchmap

  • Boron neutron capture therapy for newly diagnosed glioblastoma. 査読 国際誌

    Shinji Kawabata, Shin-Ichi Miyatake, Toshihiko Kuroiwa, Kunio Yokoyama, Atsushi Doi, Kyoko Iida, Shiro Miyata, Naosuke Nonoguchi, Hiroyuki Michiue, Masatsugu Takahashi, Taisuke Inomata, Yoshio Imahori, Mitsunori Kirihata, Yoshinori Sakurai, Akira Maruhashi, Hiroaki Kumada, Koji Ono

    Journal of radiation research   50 ( 1 )   51 - 60   2009年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    We evaluate the clinical results of a form of tumor selective particle radiation known as boron neutron capture therapy (BNCT) for newly-diagnosed glioblastoma (NDGB) patients, especially in combination with X-ray treatment (XRT). Between 2002 and 2006, we treated 21 patients of NDGB with BNCT utilizing sodium borocaptate and boronophenylalanine simultaneously. The first 10 were treated with only BNCT (protocol 1), and the last 11 were treated with BNCT followed by XRT of 20 to 30 Gy (protocol 2) to reduce the possibility of local tumor recurrence. No chemotherapy was applied until tumor progression was observed. The patients treated with BNCT (protocol 1 plus 2) showed a significant survival prolongation compared with the institutional historical controls. BNCT also showed favorable results in correspondence with the RTOG- and EORTC-RPA subclasses. The median survival time (MST) was 15.6 months for protocols 1 and 2 together. For protocol 2, the MST was 23.5 months. The main causes of death were cerebrospinal fluid dissemination as well as local recurrence. Our modified BNCT protocol showed favorable results of patients with NDGB not only for those with good prognoses but also for those with poor prognoses.

    PubMed

    researchmap

  • MICE OVEREXPRESSING DOMINANT NEGATIVE Cdk5 IN THE PANCREATIC BETA CELLS SHOW THE DIABETES MELLITUS 査読

    Yoshihiro Ohtani, Kazuhito Tomizawa, Toshio Ohshima, Hiroyuki Michiue, Teiichi Nishiki, Iori Ohmori, Hideki Matsui

    JOURNAL OF PHYSIOLOGICAL SCIENCES   59   532 - 532   2009年

     詳細を見る

    記述言語:英語   出版者・発行元:SPRINGER TOKYO  

    Web of Science

    researchmap

  • 悪性神経膠腫新規診断例におけるホウ素中性子捕捉療法の治療成績

    川端 信司, 宮武 伸一, 横山 邦生, 野々口 直助, 宮田 至朗, 黒岩 敏彦, 道上 宏之, 今堀 良夫, 切畑 光統, 小野 公二

    日本脳神経外科学会総会CD-ROM抄録集   67回   3G - 03   2008年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本脳神経外科学会  

    researchmap

  • がんに対する放射線治療の現状と展望 再発悪性神経膠腫に対する硼素中性子捕捉療法 自験22例の検討

    川端 信司, 宮武 伸一, 横山 邦生, 野々口 直助, 宮田 至朗, 黒岩 敏彦, 道上 宏之, 小野 公二

    日本癌治療学会誌   43 ( 2 )   267 - 267   2008年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本癌治療学会  

    researchmap

  • 硼素中性子捕捉療法は再発悪性グリオーマの生命予後改善に貢献しているか?

    宮武 伸一, 川端 信司, 横山 邦生, 黒岩 敏彦, 道上 宏之, 桜井 良憲, 鈴木 実, 丸橋 晃, 切畑 光統, 小野 公二

    日本脳神経外科学会総会CD-ROM抄録集   67回   3G - 04   2008年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本脳神経外科学会  

    researchmap

  • Development of bionanocapsules targeting brain tumors 査読 国際誌

    Yumi Tsutsui, Kazuhito Tomizawa, Mana Nagita, Hiroyuki Michiue, Tei-ichi Nishiki, Iori Ohmori, Masaharu Seno, Hideki Matsui

    JOURNAL OF CONTROLLED RELEASE   122 ( 2 )   159 - 164   2007年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ELSEVIER  

    Bionanocapsules (BNCs) are hollow nanoparticles that are composed of L protein (the hepatitis B virus surface antigen) and show specific affinity for human hepatocytes. The pre-S1 peptide displayed on the surface of BNCs is the specific ligand for binding to the receptor on human hepatocytes. Therefore, BNCs are not delivered to other tissues, such as the brain. The aim of the present study was to develop a novel drug delivery system (DIDS) targeting brain tumors using BNCs that selectively targeted brain tumors. Epidermal growth factor receptor (EGFR), especially a constitutively active genomic sequence deletion variant of EGFR (EGFRvIII), is overexpressed in human glioblastoma. In the present study, we replaced the pre-S1 peptide with the antibody affinity motif of protein A and made hybrid BNCs conjugated with anti-human EGFR antibody recognizing EGFRvIII. The hybrid BNCs were efficiently delivered to glioma cells but not normal glial cells. Moreover, we confirmed the specific delivery of the hybrid BNCs to brain tumors in an in vivo brain tumor model. These results suggest that this new approach using BNCs is a promising system for brain tumor-targeted drug delivery. (C) 2007 Elsevier B.V. All rights reserved.

    DOI: 10.1016/j.jconrel.2007.06.019

    Web of Science

    PubMed

    researchmap

  • 蛋白導入システム"Protein Transduction System"を利用したプロテインセラピーの発展と現状について 悪性脳腫瘍に対する蛋白導入法の利用を中心に

    道上 宏之, 富澤 一仁, 魏 范研, 松下 正之, 陸 雲飛, 市川 智継, 田宮 隆, 松井 秀樹, 伊達 勲

    岡山医学会雑誌   118 ( 3 )   205 - 208   2007年1月

  • Ubiquitination-resistant p53 protein transduction therapy facilitates anti-cancer effect on the growth of human malignant glioma cells. 査読 国際誌

    Hiroyuki Michiue, Kazuhito Tomizawa, Masayuki Matsushita, Takashi Tamiya, Yun-Fei Lu, Tomotsugu Ichikawa, Isao Date, Hideki Matsui

    FEBS letters   579 ( 18 )   3965 - 9   2005年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Protein transduction therapy using poly-arginine can deliver the bioactive p53 protein into cancer cells and inhibits the proliferation of the cells. However, one disadvantage of such therapy is the short intracellular half-life of the delivered protein. Here, we generated mutant proteins in which multiple lysine residues in the C-terminal were substituted by arginines. The mutant proteins were effectively delivered in glioma cells and were resistant to Mdm2-mediated ubiquitination. Moreover, the mutant proteins displayed higher transcription regulatory activity and powerful inhibition of the proliferation of glioma cells. These results suggest that ubiquitination-resistant p53 protein therapy may become a new effective cancer therapy.

    PubMed

    researchmap

  • The NH2 terminus of influenza virus hemagglutinin-2 subunit peptides enhances the antitumor potency of polyarginine-mediated p53 protein transduction. 査読 国際誌

    Hiroyuki Michiue, Kazuhito Tomizawa, Fan-Yan Wei, Masayuki Matsushita, Yun-Fei Lu, Tomotsugu Ichikawa, Takashi Tamiya, Isao Date, Hideki Matsui

    The Journal of biological chemistry   280 ( 9 )   8285 - 9   2005年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Protein transduction therapy is a newly developing method that allows proteins, peptides, and biologically active compounds to penetrate across the plasma membrane by being fused with cell-penetrating peptides such as polyarginine. Polyarginine-fused p53 protein penetrates across the plasma membrane of cancer cells and inhibits the growth of the cells. However, the protein is often entrapped inside macropinosomes in the cytoplasm. Therefore, high dose concentrations of the protein are needed for it to function effectively. To overcome this problem, in the present study, polyarginine-fused p53 was linked with the NH(2)-terminal domain of influenza virus hemagglutinin-2 subunit (HA2), which is a pH-dependent fusogenic peptide that induces the lysis of membranes at low pH levels. The protein was capable of efficiently translocating into the nucleus of glioma cells and induced p21(WAF1) transcriptional activity more effectively than did polyarginine-fused p53 protein. Moreover, low concentrations of the protein significantly inhibited the growth of cancer cells. These results suggest that protein transduction therapy using polyarginine and HA2 may be useful as a method for cancer therapy.

    PubMed

    researchmap

  • The relationship between peritumoral brain edema and the expression of vascular endothelial growth factor and its receptors in intracranial meningiomas. 査読 国際誌

    Shinji Otsuka, Takashi Tamiya, Yasuhiro Ono, Hiroyuki Michiue, Kazuhiko Kurozumi, Shigeru Daido, Hirokazu Kambara, Isao Date, Takashi Ohmoto

    Journal of neuro-oncology   70 ( 3 )   349 - 57   2004年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    We examined the radiological and histological features of, and the influences of the expression of VEGF and its two major receptors, Flt-1 and Flk-1, on the development of peritumoral brain edema (PTBE) in patients with intracranial meningiomas. The expressions of VEGF and VEGF receptors in the immunohistochemical study were analyzed in relation to several factors, including tumor size, location, vascularity, and blood supply, as seen on digital subtraction angiographic studies. The edema volume (P = 0.0003) and edema index (P < 0.0001) had a significantly positive relation to VEGF expression. The positivity of Flt-1 and Flk-1 was mainly observed in tumor vessels; 44 cases (37.2%) were positive for the Flt-1 antibody and 37 cases (31.4%) for the Flk-1 antibody. The mean value of the edema index of the positive-Flt-1 group (5.220 +/- 11.586) was significantly higher than that of the negative-Flt-1 group (1.782 +/- 2.559) (P < 0.0001). The mean value of the edema index of the positive-Flk-1 group (3.925 +/- 5.870) was slightly higher than that of the negative-Flk-1 group (2.671 +/- 8.136) (P < 0.0001). Our data suggest that the expressions of VEGF and VEGF receptors positively relate to each other and to the formation of PTBE in patients with meningiomas.

    PubMed

    researchmap

  • エンドソームリリーシングペプチドを利用したp53蛋白質導入法による悪性腫瘍抑制効果

    道上 宏之, 富澤 一仁, 魏 范研, 松下 正之, 陸 雲飛, 市川 智継, 田宮 隆, 伊達 勲, 松井 秀樹

    日本癌学会総会記事   63回   511 - 511   2004年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本癌学会  

    researchmap

  • Photo-acceleration of protein release from endosome in the protein transduction system. 査読 国際誌

    Masayuki Matsushita, Hirofumi Noguchi, Yun-Fei Lu, Kazuhito Tomizawa, Hiroyuki Michiue, Sheng-Tian Li, Kenzo Hirose, Susan Bonner-Weir, Hideki Matsui

    FEBS letters   572 ( 1-3 )   221 - 6   2004年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The protein transduction system has been employed for delivery of bioactive proteins into cells via an endocytotic mechanism. However, trapping of endocytosed proteins in the endosome may significantly attenuate biological actions in cells. The present investigation demonstrated that endosomal release of transduced protein could be artificially accelerated by exposure to fluorescent light. Exposure to light at 480 nm stimulated endosomal release of transduced FITC-11 arginine-protein transduction domain (11R-PTD), TAT-PTD and Antennapedia-PTD. Moreover, FITC-11R-p53 protein was released from endosomes following stimulation with light. These data suggest that photo-acceleration is a more efficient strategy in terms of the protein transduction system.

    PubMed

    researchmap

  • [Rupture of previously documented asymptomatic unruptured aneurysms--aneurysm size: risk factor for aneurysm rupture]. 査読

    Masakazu Suga, Yuji Yamamoto, Norio Sunami, Tomoyasu Abe, Hiroyuki Michiue

    No shinkei geka. Neurological surgery   30 ( 6 )   609 - 15   2002年6月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    The natural history of asymptomatic unruptured aneurysms is not clear. We conducted a follow up study of 100 patients (since 1993) with 122 asymptomatic unruptured aneurysms that had not been operated on. We report five patients with previously documented asymptomatic unruptured aneurysms smaller than 10 mm in diameter that subsequently ruptured. Among the 100 patients, five had suffered subarachnoid hemorrhage (SAH) due to rupturing of an aneurysm. Of the 5 cases, 1 was male and 4 were female, with ages ranging from 59-73 years (mean age, 68 years). The aneurysms were on the MCA in 3, on the BA-SCA in 1, on the IC-PC in 1. The maximal diameter of the aneurysms at diagnosis ranged from 4.5 to 8 mm. The period from discovery to SAH was from 4 to 69 months and the cumulative rate of rupture of the aneurysms was 1.5 percent per year. Four of the 5 cases increased in size after the rupture. In our series, 2 of the 5 cases showed enlargement and the development of an aneurysmal bleb in the follow up MRA and 3D-CTA. The present study demonstrates that five asymptomatic unruptured aneurysms less than 10 mm in diameter subsequently ruptured. We ought to seriously consider the assertion published in the New England Journal of Medicine (Dec. 10, 1998), that unruptured aneurysms less than 10 mm in diameter have a very low probability of subsequent rupture.

    PubMed

    researchmap

  • [A case of hypertrophic cranial pachymeningitis developed skull lesion]. 査読

    S Mizumatsu, H Michiue, M Suga, N Sunami, Y Yamamoto

    No to shinkei = Brain and nerve   52 ( 12 )   1103 - 8   2000年12月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    We report a case of hypertrophic cranial pachymeningitis (HCP) developed skull lesion. A 70-year-old male presented with the symptom of left hemiconvulsion. MRI revealed that the enhanced intraosseous mass infiltrated into the the dura and brain parenchyma under the parasagittal region of the right parietal bone. Histological examination revealed chronic inflammation with lymphoplasmacytic infiltrate and fibrosis of both intraosseous mass and dural invasive lesion. Steroid therapy resulted in improvement of clinical symptoms and enhanced lesion of MRI. Three years later, the patient presented with generalized convulsion and weakness of right upper and lower limbs. MRI revealed dural thickening with gadolinium enhancement in the bilateral parasagittal region and falx. Angiography showed occlusion of the superior sagittal sinus. The cause of relapsing symptoms in this patient may have been related to the occlusion of the superior sagittal sinus, due to HCP. We considered that the incipient intraosseous mass resulted from a response of the marrow by destructive progression of chronic inflammation passed through the fracture crack or the cavity of arachnoid granulation.

    PubMed

    researchmap

▼全件表示

MISC

  • BNCT応用へ向けた即発γ線分析による非観血的生体内ホウ素薬物動態測定技術の開発

    道上宏之, 櫻井良憲, 北松瑞生

    中谷医工計測技術振興財団年報   ( 34 )   2021年

     詳細を見る

  • 細胞内局在を標的とした新規ホウ素製剤が切り拓く次世代BNCT

    藤村篤史, 藤村篤史, 井川和代, 植田愛, 渡辺香里, 道上宏之, 市川康明, 古矢修一

    月刊メディカル・サイエンス・ダイジェスト   46 ( 8 )   2020年

     詳細を見る

  • Peptide Zipperingを介した新規タンパク質細胞内導入法の検討

    湯浅啓生, 道上宏之, 北松瑞生, 松下博昭, 西木禎一, 松井秀樹

    日本生理学雑誌(Web)   78 ( 1 )   2016年

     詳細を見る

  • 抗うつ薬フルボキサミンを用いた悪性グリオーマ治療法の開発

    道上宏之, 道上宏之, 林佳一郎, 山田浩司, 黒住和彦, 市川智継, 松下博昭, 西木禎一, 松井秀樹

    日本脳腫瘍学会プログラム・抄録集   34th   2016年

     詳細を見る

  • 低酸素安定化ドメインを用いた脳腫瘍治療ペプチドの開発

    山口貴博, 道上宏之, 北松瑞生, 松下博昭, 西木禎一, 松井秀樹

    日本生理学雑誌(Web)   78 ( 1 )   2016年

     詳細を見る

  • 神経伝達物質放出のCa2+センサーDoc2の神経系における局在解析

    岩藤亮太, 藤野加奈子, 西木禎一, 松下博昭, 道上宏之, 高橋正身, 松井秀樹

    日本生理学雑誌(Web)   78 ( 1 )   2016年

     詳細を見る

  • 悪性黒色腫に対する抗腫瘍p53 Fragment Peptideスクリーニングと経皮的導入による治療効果の検討

    澄田憲祐, 道上宏之, 北松瑞生, 松下博昭, 西木禎一, 松井秀樹

    日本生理学雑誌   77 ( 1 (Web) )   2015年

     詳細を見る

  • 抗血管新生療法に対する脳腫瘍幹細胞由来腫瘍血管の反応

    道上宏之, 中山大輝, 松下博昭, 西木禎一, 松井秀樹

    日本脳腫瘍学会プログラム・抄録集   33rd   2015年

     詳細を見る

  • 脳血液関門通過可能なアクチン重合抑制薬による膠芽腫に対する抗浸潤効果の検討

    道上宏之, 林桂一郎, 山田浩司, 中山大輝, 黒住和彦, 市川智継, 松下博昭, 西木禎一, 竹居孝二, 富澤一仁, 松井秀樹

    日本脳腫瘍学会プログラム・抄録集   32nd   2014年

     詳細を見る

  • Trans-Dermal Approachの可能性 : 発毛促進ペプチドを例として (特集 毛髪のエイジングケア研究と育毛剤の開発)

    道上 宏之, 藤村 篤史, 松井 秀樹

    Fragrance journal   41 ( 11 )   23 - 27   2013年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:フレグランスジャーナル社  

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2014075956

  • ヘテロ二量体化ロイシンジッパーによる緑色蛍光タンパク質の細胞内輸送

    出口宝, 北松瑞生, 中島真実, 大槻高史, 道上宏之

    日本化学会講演予稿集   93rd ( 3 )   2013年

     詳細を見る

▼全件表示

講演・口頭発表等

  • ホウ素薬剤開発に基づくこれからのBNCT戦略 招待

    道上宏之

    岡山大学中性子医療研究センター 第5回シンポジウム「BNCTが拓いた新たながん治療の展開」  2021年12月10日 

     詳細を見る

    開催年月日: 2021年12月10日

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(指名)  

    researchmap

  • BSH/ペプチドDDSによる新規ホウ素薬剤開発

    道上宏之

    第17回日本中性子捕捉療法学会  2021年7月10日 

     詳細を見る

    開催年月日: 2021年7月10日 - 2021年7月11日

    記述言語:英語   会議種別:口頭発表(一般)  

    researchmap

  • 両親媒性ペプチドを用いたホウ素ペプチド創薬 招待

    道上宏之

    シンポジウム「ペプチドの新たな未来へ向けて」  2021年3月2日 

     詳細を見る

    開催年月日: 2021年3月2日

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(指名)  

    researchmap

  • “ホウ素”と “ペプチド”で がんをやっつける! がん治療法・BNCTに利用可能なホウ素薬剤の 高性能な新薬を開発 招待

    道上宏之

    岡山大学プレスリリース  2020年12月17日 

     詳細を見る

    開催年月日: 2020年12月17日

    記述言語:日本語   会議種別:メディア報道等  

    researchmap

  • 「ホウ素薬剤開発の現状 ~基礎研究より橋渡し研究へ向けて~ 招待

    道上宏之

    令和2年度 第1回量子医療研究会  2020年8月22日 

     詳細を見る

    開催年月日: 2020年8月22日

    会議種別:口頭発表(招待・特別)  

    researchmap

  • Translational research in hair generation from lab to life 招待

    道上 宏之

    National Symposium and Workshop in Anti-Aging Medicine committee  2020年2月8日 

     詳細を見る

    開催年月日: 2020年2月7日 - 2020年2月9日

    記述言語:英語   会議種別:口頭発表(招待・特別)  

    researchmap

  • The role of calcineurin in controlling cell function in hair generation 招待

    道上 宏之

    National Symposium and Workshop in Anti-Aging Medicine  2020年2月8日 

     詳細を見る

    開催年月日: 2020年2月7日 - 2020年2月9日

    記述言語:英語   会議種別:口頭発表(招待・特別)  

    researchmap

  • ペプチドDDSを用いた新規ホウ素薬剤製剤化への取り組み

    道上 宏之

    第3回中性子医療研究センターシンポジウム  2019年12月10日 

     詳細を見る

    開催年月日: 2019年12月10日

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(指名)  

    researchmap

  • New boron(10B) drugs against GBM 招待

    道上 宏之

    SickKids Hospital Reserch meeting organized by the Labatt Brain Tumor Research Centre  2019年11月27日 

     詳細を見る

    開催年月日: 2019年11月27日

    記述言語:英語   会議種別:口頭発表(招待・特別)  

    researchmap

  • New drug discovery with drug re-positioning system toward GBM treatment

    道上 宏之

    the 24th Annual Meeting of the Society for Neuro-Oncology  2019年11月22日 

     詳細を見る

    開催年月日: 2019年11月21日 - 2019年11月24日

    記述言語:英語   会議種別:ポスター発表  

    researchmap

  • New peptide Drug Delivery System with BSH toward future BNCT clinical application

    H. Michiue, A. Fukunaga, M. Kitamatsu, N. Kondo, Y. Sakurai, A. Fujimura, K. Igawa, H. Matsui, S. Furuya

    10th Young Researchers BNCT meeting  2019年9月26日 

     詳細を見る

    開催年月日: 2019年9月26日 - 2019年9月29日

    記述言語:英語   会議種別:口頭発表(一般)  

    researchmap

  • The cell biological evaluation with Nagoya University BNCT system

    道上宏之, 井川和代, 古矢修一, 市川康明, 吉橋幸子, 瓜谷章, 渡辺賢一, 鬼柳善明, 土田一輝

    第16回日本中性子捕捉療法学会学術大会  2019年9月7日 

     詳細を見る

    開催年月日: 2019年9月7日 - 2019年9月8日

    記述言語:英語   会議種別:ポスター発表  

    researchmap

  • BNCTを用いた新規岡山大学メラノーマ集学的治療へ向けた取り組み 招待

    道上 宏之

    第2回中性子医療研究センターシンポジウム  2018年12月12日 

     詳細を見る

    開催年月日: 2018年12月12日

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(指名)  

    researchmap

  • 脳腫瘍幹細胞由来の腫瘍血管を標的とした新規抗血管新生療法の開発

    道上宏之, 中山大輝, 立壁賢, 黒住和彦, 藤井謙太郎, 松井秀樹

    第36回日本脳腫瘍学会学術集会  2018年12月2日 

     詳細を見る

    開催年月日: 2018年12月2日 - 2018年12月4日

    記述言語:英語   会議種別:口頭発表(一般)  

    researchmap

  • New A6k boron drug delivery system for clinical application

    H. Michiue, A. Fukunaga, A. Fujimura, K. Igawa, H. Matsui, S. Furuya

    2018 Annual Meeting and Education Day of the Society for Neuro-Oncology.  2018年11月17日 

     詳細を見る

    開催年月日: 2018年11月15日 - 2018年11月18日

    記述言語:英語   会議種別:ポスター発表  

    researchmap

  • New self-assembling peptide Drug Delivery System with BSH toward clinical application

    Hiroyuki Michiue, Asami Fukunaga, Atsushi Fujimura, Kazuyo Igawa, Shuichi Furuya, Hideki Matsui

    18th International Congress on Neutron Capture Therapy  2018年10月28日 

     詳細を見る

    開催年月日: 2018年10月27日 - 2018年11月1日

    記述言語:英語   会議種別:口頭発表(一般)  

    researchmap

  • メラノーマへのホウ素中性子捕捉療法(BNCT)を含む新規集学的治療法の方向性 招待

    道上 宏之

    第77回日本癌学会学術総会  2018年9月28日 

     詳細を見る

    開催年月日: 2018年9月27日 - 2018年9月29日

    記述言語:英語   会議種別:口頭発表(招待・特別)  

    researchmap

  • 岡山大学中性子医療研究センターによるBNCTの新しい挑戦 招待

    道上 宏之

    BNCTなかもずセミナー  2018年9月6日 

     詳細を見る

    開催年月日: 2018年9月6日

    記述言語:日本語   会議種別:口頭発表(招待・特別)  

    researchmap

  • ペプチドDDS を用いた新規ホウ素薬剤の構築

    道上 宏之, 福永 麻美, 北松 瑞生, 近藤 夏子, 櫻井 良憲, 藤村 篤史, 井川 和代, 松井 秀樹, 古矢 修一

    第15回日本中性子捕捉療法学会学術大会  2018年9月1日 

     詳細を見る

    開催年月日: 2018年9月1日 - 2018年9月2日

    記述言語:英語   会議種別:口頭発表(一般)  

    researchmap

  • 再発メラノーマに対するBNCTを含めた新規集学的治療の取り組み

    道上 宏之

    第22回日本がん免疫学会総会  2018年8月2日 

     詳細を見る

    開催年月日: 2018年8月1日 - 2018年8月3日

    記述言語:日本語   会議種別:ポスター発表  

    researchmap

  • メラノーマ治療におけるホウ素中性子捕捉療法(BNCT) ~BNCTの基礎より最新の研究まで~ 招待

    道上 宏之

    第6回岡山メラノーマ治療研究会  2018年5月22日 

     詳細を見る

    開催年月日: 2018年5月22日

    記述言語:日本語   会議種別:口頭発表(招待・特別)  

    researchmap

  • The function of brain tumor stem cell 招待

    H. Michiue

    第95回日本生理学会大会  2018年3月28日 

     詳細を見る

    開催年月日: 2018年3月28日 - 2018年3月30日

    記述言語:英語   会議種別:口頭発表(招待・特別)  

    researchmap

  • 現状の標準治療と課題、BNCTに対する期待 招待

    道上 宏之

    第1回中性子医療研究センターシンポジウム  2017年12月5日 

     詳細を見る

    開催年月日: 2017年12月5日

    記述言語:日本語   会議種別:口頭発表(招待・特別)  

    researchmap

  • Anti-depressant, SSRI found by drug repositioning system, blocked glioblastoma invasion with targeting to inhibit actin polymerization

    Hiroyuki Michiue, Keiichiro Hayashi, Atsushi Fujimura, Hiroaki Matsushita, Tei-ichi Nishiki, Hideki Matsui

    22ND ANNUAL SCIENTIFIC MEETING AND EDUCATION DAY OF THE SOCIETY FOR NEURO-ONCOLOGY  2017年11月18日 

     詳細を見る

    開催年月日: 2017年11月16日 - 2017年11月19日

    記述言語:英語   会議種別:ポスター発表  

    researchmap

  • The next generation Boron agents with BSH fused Cell Penetrating Peptide toward clinical application

    Hiroyuki Michiue, Mizuki Kitamatsu, Natsuko Kondo, Yoshinori Sakurai, Hideki Matsui

    9th Young Researchers' BNCT Meeting  2017年11月14日 

     詳細を見る

    開催年月日: 2017年11月13日 - 2017年11月15日

    記述言語:英語   会議種別:口頭発表(一般)  

    researchmap

  • ホウ素を用いた新しいがん治療法BNCTと新規ホウ素薬剤開発 招待

    道上 宏之

    メタルバイオサイエンス研究会2017  2017年10月14日 

     詳細を見る

    開催年月日: 2017年10月13日 - 2017年10月14日

    記述言語:日本語   会議種別:口頭発表(招待・特別)  

    researchmap

  • :細胞膜通過ペプチド(CPP)を用いた新規ホウ素薬剤開発の展望

    道上宏之, 北松瑞生, 櫻井良憲, 近藤夏子, 藤村篤史, 松下博昭, 西木禎一, 市川康明, 松井秀樹

    第14回日本中性子捕捉療法学会学術大会  2017年9月29日 

     詳細を見る

    開催年月日: 2017年9月29日 - 2017年9月30日

    記述言語:英語   会議種別:口頭発表(一般)  

    researchmap

  • BNCTの基礎と岡山大学中性子医療研究センターについて

    道上宏之

    岡山大学医学部技術部研修会  2017年8月28日 

     詳細を見る

    開催年月日: 2017年8月28日

    記述言語:日本語   会議種別:口頭発表(招待・特別)  

    researchmap

  • The peptide transdermal therapy against melanoma with a novel p53 peptide screened from p53-overlapping fragment peptide library

    Hiroyuki Michiue, Mizuki Kitamatsu, Kensuke Sumita Hiroaki, Matsusita Tei-ichi Nishiki Hideki Matsui

    The 25th America Peptide Symposium  2017年6月19日 

     詳細を見る

    開催年月日: 2017年6月17日 - 2017年6月22日

    記述言語:英語   会議種別:ポスター発表  

    researchmap

▼全件表示

産業財産権

  • グルコース結合ホウ素薬剤

    道上 宏之, 高口 豊

     詳細を見る

    出願人:国立大学法人 岡山大学

    出願番号:特願2021-046789  出願日:2021年3月22日

    公開番号:特開2021-152000  公開日:2021年9月30日

    J-GLOBAL

    researchmap

  • ホウ素含有化合物およびそれを含む薬剤

    北松 瑞生, 副島 哲朗, 山形 尚紀, 道上 宏之, 大槻 高史

     詳細を見る

    出願人:学校法人近畿大学

    出願番号:特願2019-196902  出願日:2019年10月30日

    公開番号:特開2020-117479  公開日:2020年8月6日

    J-GLOBAL

    researchmap

  • ホウ素中性子捕捉療法のための新規BSH複合体

    松井 秀樹, 古矢 修一, 道上 宏之, 加来田 博貴, 竹内 康明

     詳細を見る

    出願人:国立大学法人 岡山大学

    出願番号:特願2018-553029  出願日:2017年11月24日

    特許番号/登録番号:特許第6548060号  登録日:2019年7月5日 

    J-GLOBAL

    researchmap

  • 血管新生阻害薬

    道上 宏之, 松井 秀樹, 立壁 賢

     詳細を見る

    出願人:国立大学法人 岡山大学

    出願番号:特願2017-065166  出願日:2017年3月29日

    公開番号:特開2017-178943  公開日:2017年10月5日

    特許番号/登録番号:特許第6952980号  登録日:2021年10月1日 

    J-GLOBAL

    researchmap

  • 細胞内導入機能を有するホウ素を含むデンドリマー

    道上 宏之, 福永 麻美, 松井 秀樹, 高口 豊, 田嶋 智之, 石本 寛伍, 大津 裕貴

     詳細を見る

    出願人:国立大学法人 岡山大学

    出願番号:特願2017-038462  出願日:2017年3月1日

    公開番号:特開2018-145107  公開日:2018年9月20日

    J-GLOBAL

    researchmap

  • 細胞膜透過型ホウ素ペプチド

    道上 宏之, 松井 秀樹, 北松 瑞生, 王 飛霏, 富澤 一仁

     詳細を見る

    出願人:国立大学法人 岡山大学

    出願番号:特願2016-140473  出願日:2016年7月15日

    公開番号:特開2016-204378  公開日:2016年12月8日

    特許番号/登録番号:特許第6320469号  登録日:2018年4月13日 

    J-GLOBAL

    researchmap

  • 電子書籍表示装置、電子書籍表示方法、及び、電子書籍表示システム

    道上 徹

     詳細を見る

    出願人:京セラドキュメントソリューションズ株式会社

    出願番号:特願2015-193130  出願日:2015年9月30日

    公開番号:特開2017-068012  公開日:2017年4月6日

    J-GLOBAL

    researchmap

  • PET用ホウ素化合物

    道上 宏之, 井口 佳哉, 松井 秀樹, 富澤 一仁, 北松 瑞生

     詳細を見る

    出願人:国立大学法人 岡山大学

    出願番号:特願2014-144412  出願日:2014年7月14日

    公開番号:特開2016-020316  公開日:2016年2月4日

    J-GLOBAL

    researchmap

  • 抗がん剤

    道上 宏之, 松井 秀樹, 林 桂一郎, 竹居 孝二, 山田 浩司, 宮地 弘幸, 浅井 章良

     詳細を見る

    出願人:国立大学法人 岡山大学

    出願番号:特願2012-263317  出願日:2012年11月30日

    公開番号:特開2014-108930  公開日:2014年6月12日

    特許番号/登録番号:特許第5922563号  登録日:2016年4月22日 

    J-GLOBAL

    researchmap

  • 新規ペプチド複合体、そのハイブリッド複合体およびその用途

    北松 瑞生, 道上 宏之, 王 飛霏, 中島 真実, 大槻 高史

     詳細を見る

    出願人:国立大学法人 岡山大学

    出願番号:JP2012076654  出願日:2012年10月16日

    公表番号:WO2013-061818  公表日:2013年5月2日

    J-GLOBAL

    researchmap

  • 細胞導入ペプチドと皮膚導入促進剤とを組み合わせた皮膚導入システムおよび美白剤

    松井 秀樹, 道上 宏之, 石川 早苗

     詳細を見る

    出願人:国立大学法人 岡山大学

    出願番号:特願2013-531360  出願日:2012年8月29日

    特許番号/登録番号:特許第5940542号  登録日:2016年5月27日 

    J-GLOBAL

    researchmap

  • 抗浸潤薬の新規スクリーニング法

    山田 浩司, 道上 宏之, 竹居 孝二, 松井 秀樹, 浅井 章良

     詳細を見る

    出願人:国立大学法人 岡山大学

    出願番号:特願2012-137489  出願日:2012年6月19日

    公開番号:特開2014-002043  公開日:2014年1月9日

    特許番号/登録番号:特許第5806168号  登録日:2015年9月11日 

    J-GLOBAL

    researchmap

▼全件表示

受賞

  • 15th International Congress of Radiation Research Excellent Poster Award

    2015年5月   15th International Congress of Radiation Research   The Development of BSH Fused Cell-penetrating Peptide towards Clinical Application

    Hiroyuki Michiue, Yoshiya Iguchi, Mizuki Kitamatsu, Hiroaki Matsushita, Tei-ichi Nishiki, Hideki Matsui

     詳細を見る

  • 岡山医学会賞総合研究奨励賞(結城賞)

    2014年6月   岡山医学会   細胞膜通過ペプチド付加BSHホウ素化合物は 中性子捕捉療法の発展につながる

    道上宏之

     詳細を見る

  • 日本生理学会中四国地方会奨励賞(研究者部門)

    2010年11月   日本生理学会   タンパク質導入法を用いた新規siRNA導入法の開発

    道上宏之

     詳細を見る

  • 岡山医学会賞(山田賞)

    2006年6月   岡山医学会  

     詳細を見る

  • 中国経済連合会長賞

    2005年1月   第3回キャンパスベンチャーグランプリ中国大会   蛋白質による細胞機能制御と実用化

    道上宏之, 魏 范研, 藤田梨嘉

     詳細を見る

共同研究・競争的資金等の研究

  • BNCT併用メラノーマ複合免疫療法へ向けた前臨床探索研究と新規ホウ素薬剤開発

    研究課題/領域番号:20K08652  2020年04月 - 2023年03月

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    山崎 修, 道上 宏之

      詳細を見る

    配分額:4290000円 ( 直接経費:3300000円 、 間接経費:990000円 )

    researchmap

  • 難治性消化器がんを標的としたホウ素中性子捕捉療法の開発と効果予測マーカーの探索

    研究課題/領域番号:19K09122  2019年04月 - 2022年03月

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    寺石 文則, 藤原 俊義, 道上 宏之, 重安 邦俊

      詳細を見る

    配分額:4160000円 ( 直接経費:3200000円 、 間接経費:960000円 )

    researchmap

  • 細胞内局在を標的とした新規ホウ素薬剤の開発とBNCT

    研究課題/領域番号:18K07324  2018年04月 - 2021年03月

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    市川 康明, 道上 宏之

      詳細を見る

    配分額:4290000円 ( 直接経費:3300000円 、 間接経費:990000円 )

    次世代のがん治療であるホウ素中性子捕捉療法(Boron Neutron Capture Therapy, BNCT)は、ホウ素を取込ませたがん細胞に中性子線を照射し、ホウ素と中性子の核反応により細胞を破壊する。BNCTの中性子源としては1950年代から利用されてきた原子炉に代わり、中性子発生装置の一部が企業治験段階に進み、今後のBNCTの成功の可否はホウ素薬剤に大きく依存する。BNCTにより発生した数マイクロメートル飛程の2次粒子は、腫瘍細胞へ細胞障害を誘導する際に、ホウ素薬剤が細胞のどの位置(細胞外膜、細胞質、核膜、ミトコンドリア、核内など)に局在するかによりその効果が異なると、これまで報告してきた。現在治験中薬剤BPA(ホウ素フェニルアラニン)はアミノ酸フェニルアラニンに1個のホウ素が結合したホウ素アミノ酸誘導体である。腫瘍細胞は、正常細胞と比較して一般的にアミノ酸代謝が亢進しており、様々なアミノ酸取り込みが高いとされている。同様にフェニルアラニンの誘導体であるBPAも腫瘍に特異的に取り込まれ、さらに正常細胞と比較して腫瘍細胞にフェニルアラニンの取り込みを行うアミノ酸トランスポーターLAT1が強発現していることより、BPAは腫瘍特異的なホウ素分子標的薬とも言える。アミノ酸を標的としたホウ素薬剤は非常に素晴らしい取り込み能を示している一方で、腫瘍細胞の中には、一部取り込み能の低いものも存在し、BNCT後の再発の原因となっている。我々は、これまで細胞内導入困難とされてきたホウ素12個からなる正20面体構造を有するホウ素立体分子BSH(Na2B12H11SH)をアミノ酸・ペプチド修飾することにより細胞内導入することに成功した。本薬剤を用いて、中性子照射により生じる殺細胞効果を細胞内のホウ素薬剤の細胞内小器官の局在の見地より評価し、今後のホウ素薬剤開発への発展へ繋げる。

    researchmap

  • ドラッグリポジショニングを用いた非VEGF経路に対する新規抗血管新生薬開発

    研究課題/領域番号:18K08944  2018年04月 - 2021年03月

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    道上 宏之

      詳細を見る

    配分額:4420000円 ( 直接経費:3400000円 、 間接経費:1020000円 )

    現在の悪性脳腫瘍治療では外科手術、放射線療法、化学療法を用いた集学的治療である。最も悪性度の高い膠芽腫では治療技術の発達向上にもかかわらず、平均生存期間約1年数か月、5年生存率数%と極めて予後不良である。また、悪性腫瘍への抗血管新生療法の概念は古く1970年代より提唱されており、抗ヒトVEGFモノクローナル抗体のベバシズマブ(アバスチン; 中外製薬)が、国内外において切除不能進行・再発大腸癌に対する標準治療と認可された後、卵巣癌、非小細胞肺癌、子宮頸癌等に対しても承認されている。悪性脳腫瘍(膠芽腫)に対する抗血管新生薬を用いた代表的な北米臨床試験AVAglio studyにて、標準治療に抗血管新生薬アバスチン(ベバシズマブ)追加群に生存期間延長は認めなかった。そこで我々は、膠芽腫の抗血管新生療法抵抗性の原因の一つが、がん血管新生阻害薬の多くの作用点がVEGFR/VEGF-R経路にあることに着目した。言うまでも無く、VEGF経路は腫瘍血管新生において最も中心的役割果たす代表的な経路である。そこで我々は、「悪性脳腫瘍において、VEGFは腫瘍血管形成において重要な経路であるが、VEGF経路が阻害されても非VEGF経路により腫瘍血管形成が代償される機構が存在し、腫瘍血管は維持され、そのためアバスチン単独では抗血管新生治療による予後延長が得られない」との、仮説を立て実験を行った。抗血管新生薬を用いた抗血管新生療法は、理論として問題なく、抑制する経路が腫瘍により異なるのではないかと考えられた。本プロジェクトにより、VEGF非依存的な血管新生の経路を同定し、ドラッグリポジショニングに基づく阻害薬発見を行う予定である。

    researchmap

  • 再発悪性グリオーマ予後不良群に対するBNCTとベバシズマブ併用臨床試験

    研究課題/領域番号:17K10877  2017年04月 - 2020年03月

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    宮武 伸一, 近藤 夏子, 川端 信司, 道上 宏之, 古瀬 元雅

      詳細を見る

    配分額:4680000円 ( 直接経費:3600000円 、 間接経費:1080000円 )

    再発悪性グリオーマの予後は不良であり、標準治療は存在しない。ことに予後不良再発群(J Clin Oncol 25:2601-2606, 2007,以下JCO RPA 3+7群)は、再発後に何らかの補助治療を施行してもその治療以降の生存期間中央値が4.4ヶ月と極めて不良である。この予後不良再発悪性グリオーマに対象を絞って、その予後を改善するために、二つの治療、すなわちホウ素中性子捕捉療法およびベバシズマブ投与のコンビネーションによる臨床試験を行い、その治療効果を明らかにし、ひいては将来の加速器中性子源を用いた再発悪性グリオーマに対する標準治療への布石にすることが本研究の目的である。
    平成29,30年度とも以下のプロトコールに従い、再発悪性グリオーマ(MG)予後不良群(JCO,RPA 3+7群+Bev使用後再発群)に対して、原子炉BNCTを施行し、その2-4週後より、Bev10mg/kg, biweekly の投与をRANOの診断基準での悪化まで継続し、全生存(OS)を主要評価項目として、single arm, 第二相臨床試験を行う。以上の研究計画を実施予定としており、プロトコールの確立を医療イノベーション推進センター(旧称臨床研究情報センター)とともに行い、CRFも作成し、電子入力システムを構築した。平成29年8月に京都大学原子炉(KUR)が再開後、UMIN上にも本臨床試験を公開し、患者entry を開始したが、その直後からKURが施設上の不具合が発生し臨床試験を2ヶ月間休止せざるを得なかった。現在までに4例の症例のentry を行い、follow-up中である。

    researchmap

  • 中枢神経系疾患における神経新生とうつ症状:細胞移植、電気刺激、リハビリによる治療

    研究課題/領域番号:17H04303  2017年04月 - 2020年03月

    日本学術振興会  科学研究費助成事業 基盤研究(B)  基盤研究(B)

    伊達 勲, 黒住 和彦, 道上 宏之, 藤井 謙太郎, 安原 隆雄, 亀田 雅博, 菱川 朋人, 田尻 直輝, 市川 智継

      詳細を見る

    配分額:17030000円 ( 直接経費:13100000円 、 間接経費:3930000円 )

    平成30年度も順調に研究が進んだと言える。特筆すべきは、カプセル化細胞移植による、うつ病モデルラットに対する治療効果を示すことができたことである。(Kin K, et al. Mol Pshychiatry 2018) カプセル化骨髄幹細胞移植により、うつ病モデルラット脳内の神経新生が増幅され、うつ病様行動も改善を示した。そのメカニズムの一つとして、カプセル化細胞移植によって、脳内の神経栄養因子や成長因子濃度が上昇し、シグナルが活性化されたことも明らかにすることができた。また、リチウムとセロトニン再取り込み阻害剤の併用療法による治療効果メカニズムについても検討を進めた。(投稿中)パーキンソン病モデルラットに対する電気刺激研究においても、脊髄硬膜外刺激、迷走神経刺激両社によって明らかな治療効果が行動学的、組織学的に示されており、現在論文執筆中であり、次年度には掲載が見込まれる。特に、小型・持続電気刺激が可能であり、刺激調整も可能な電気刺激システムを用いており、極めて臨床での電気刺激に近似した実験系を確立したことは意義深い。一方で、脳梗塞モデルラットにおけるうつ様行動の解析は、厳しい状況にあると言える。うつ病モデルとして用いているWistar Kyoto ratは虚血耐性があり、均一な脳梗塞を作製することが難しく、そのために、うつ病様行動にも相当なばらつきが出てしまうことが明確になった。Wistar Kyoto ratにおける両側頚動脈閉塞による低灌流モデルでは明確なうつ様行動に与える影響が得られなかった。現在、Wistar ratを用いた脳梗塞モデルを用いて、うつ病様行動の解析を現在行っており、神経新生との関与を検討している。

    researchmap

  • ペプチドジッパー法により細胞内運搬したタンパク質や機能性ペプチドの効果的機能改善

    研究課題/領域番号:16K05856  2016年04月 - 2019年03月

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    北松 瑞生, 道上 宏之, 博多 義之

      詳細を見る

    配分額:4940000円 ( 直接経費:3800000円 、 間接経費:1140000円 )

    申請者は、細胞内に薬剤となるタンパク質や機能性ペプチドを安全にかつ効率的に運搬することによって、病気を治療することを目的にしている。今回申請者は、Nanogタンパク質とヘテロ二量体化ロイシンジッパーペプチド(LzK)を連結させた。また、細胞内運搬ペプチドとLzKの対となるペプチド(LzE)を連結させた。これらのペプチドを混ぜるとNanogタンパク質が細胞質内、さらには核膜内に運搬されて、Nanogの持つ機能をうまく発現させることができた。

    researchmap

  • 脳梗塞におけるうつ症状と神経新生

    研究課題/領域番号:16K10722  2016年04月 - 2019年03月

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    安原 隆雄, 市川 智継, 黒住 和彦, 道上 宏之, 亀田 雅博, 上利 崇, 菱川 朋人, 佐々木 達也, 藤井 謙太郎

      詳細を見る

    配分額:4550000円 ( 直接経費:3500000円 、 間接経費:1050000円 )

    うつ病・うつ状態は、現代のストレス社会において大きな問題であり、メカニズムの解明や新しい治療法が望まれる。私たちはうつ病モデルラットを用いた研究で、次のことを明らかにした。1.うつ病様行動を示すWistar Kyoto ratでは、海馬における神経新生が減弱していた。2.うつ病様行動を示すWistar Kyoto ratに対して、側脳室内にカプセル化骨髄幹細胞移植を行うと、うつ病様行動の改善や神経新生の増強が認められた。3.上記2の治療効果のメカニズムは、様々な神経栄養因子や成長因子がカプセル化細胞から分泌されることによると考えられた。

    researchmap

  • ドラッグ・リポジショニングによる悪性グリオーマの抗浸潤分子標的薬の開発

    研究課題/領域番号:16K10756  2016年04月 - 2019年03月

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    阿部 匡史, 道上 宏之, 竹居 孝二, 山田 浩司

      詳細を見る

    配分額:4810000円 ( 直接経費:3700000円 、 間接経費:1110000円 )

    悪性グリオーマの治療において、腫瘍細胞の強い浸潤能が外科手術における有効な病巣の切除の妨げとなる。この浸潤能を抑制する目的で、グリオーマ細胞に対して抗浸潤作用を持つダイナミン阻害剤(抗うつ剤:フルボキサミン)をドラッグ・リポジショニングにより同定した。また、フルボキサミンをリード分子としてダイナミン阻害剤のスクリーニングを進めた。さらに、グリオーマ細胞の浸潤にはダイナミン-コルタクチン複合体によるアクチン線維束形成が重要であること、この束化の調節にはサイクリン依存性キナーゼによるコルタクチンのリン酸化が関与することを明らかにした。

    researchmap

  • 脳腫瘍幹細胞標的型ホウ素ペプチドを用いた新しいホウ素中性子捕捉療法

    研究課題/領域番号:15K10333  2015年04月 - 2018年03月

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    道上 宏之, 北松 瑞生

      詳細を見る

    配分額:4810000円 ( 直接経費:3700000円 、 間接経費:1110000円 )

    我々は、先行研究にて細胞膜透過機能を有するペプチド CPPを複数個のBSHと結合させたmulti-BSH-CPPを作成した。本プロジェクトにて、臨床応用へ向けて、さらに臨床応用へ向けたホウ素製剤へ向けて発展を行った。
    a) 最小CPPを結合させたホウ素化合物BSH-3Rの開発に成功した。合成上非常に簡便であり、臨床応用な化合物である。 b)BSH-3Rは腫瘍内部への取り込み能を有しており、さらに時間経過により、核へと導入が確認された。c)本薬剤の動物における薬物動態評価を行うために、金属キレーター及び放射線各種64Cuを用いた、BSH-3R-DOTA-64CuのPET用プローブを作成した。

    researchmap

  • がん幹細胞を標的とした中性子捕捉剤と分子イメージング技術の開発

    研究課題/領域番号:15H04906  2015年04月 - 2018年03月

    日本学術振興会  科学研究費助成事業 基盤研究(B)  基盤研究(B)

    松井 秀樹, 道上 宏之, 宮武 伸一, 松下 博昭, 北松 瑞生

      詳細を見る

    配分額:17680000円 ( 直接経費:13600000円 、 間接経費:4080000円 )

    自己会合性ペプチドを薬剤送達方法として利用し、これにホウ素剤を添加して送達する技術を創生した。この手法により培養した悪性神経膠芽腫ならびに培養乳がん細胞に対しホウ素剤を導入できる事を示した。本法はがん幹細胞への特異性がより高いことを示した。In vivo脳腫瘍モデルマウスを作成し、このモデルマウスに対して、ホウ素導入薬剤を尾静脈から注射すると、ホウ素が腫瘍内に導入され蓄積する事を示した。ホウ素剤に陽イオンキレータを結合させ、これを介して64Cu同位体を結合させ、これが分子イメージング試薬として機能する事を示した。

    researchmap

  • 中枢神経系疾患に対する細胞移植の臨床応用の扉を開く:カプセル化と電気刺激を用いて

    研究課題/領域番号:26293323  2014年04月 - 2017年03月

    日本学術振興会  科学研究費助成事業 基盤研究(B)  基盤研究(B)

    伊達 勲, 黒住 和彦, 道上 宏之, 近藤 聡彦, 安原 隆雄, 亀田 雅博, 上利 崇, 菱川 朋人

      詳細を見る

    配分額:15860000円 ( 直接経費:12200000円 、 間接経費:3660000円 )

    パーキンソン病モデル動物に対する脊髄刺激治療の治療効果を明らかにした。脳梗塞モデル動物に対する経頚動脈的骨髄幹細胞移植治療において、発症から24時間後の移植が高い治療効果を示すことを明らかにした。脳梗塞モデル動物に対する細胞移植と電気刺激治療を組み合わせた研究では、移植細胞の脳梗塞への遊走は電気刺激により増強され、行動学的・組織学的に治療効果も明らかにされた。

    researchmap

  • ヘテロ二量体化ロイシンジッパー法によるタンパク質の細胞内運搬技術の開発

    研究課題/領域番号:25410181  2013年04月 - 2016年03月

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    北松 瑞生, 道上 宏之

      詳細を見る

    配分額:5330000円 ( 直接経費:4100000円 、 間接経費:1230000円 )

    申請者は、病気の治療を目的として、細胞内に機能性タンパク質や機能性ペプチドを運搬する方法の開発を目指している。今回申請者は、オートファジー誘導ペプチド(Beclin 1)とヘテロ二量体化ロイシンジッパーペプチド(LzK)を連結させた。また、細胞内運搬ペプチドとLzKの対となるペプチド(LzE)を連結させた。これらのペプチドは混ぜると、Beclin 1が細胞内に運搬され、オートファジーを誘導できた。

    researchmap

  • ペプチドDDSを用いた新規ホウ素製剤による悪性脳腫瘍治療研究

    研究課題/領域番号:24791502  2012年04月 - 2015年03月

    日本学術振興会  科学研究費助成事業 若手研究(B)  若手研究(B)

    道上 宏之

      詳細を見る

    配分額:4290000円 ( 直接経費:3300000円 、 間接経費:990000円 )

    ホウ素中性子捕捉療法(BNCT)は、悪性腫瘍細胞に対してホウ素を取りこませ、中性子照射により、腫瘍殺傷効果を得る治療法である。本研究は「ホウ素製剤を悪性脳腫瘍細胞内部に、そして、腫瘍選択的にペプチドを用いて運搬し、中性子照射により腫瘍を効率よく殺傷する」ことを主目的とする。本研究の成果はペプチドベクターを用いた薬剤運搬のための革新的方法となる。

    researchmap

  • 腫瘍選択性を有するテーラーメイド型の中性子捕捉剤の開発

    研究課題/領域番号:24390293  2012年04月 - 2015年03月

    日本学術振興会  科学研究費助成事業 基盤研究(B)  基盤研究(B)

    松井 秀樹, 道上 宏之, 小野 公二, 宮武 伸一

      詳細を見る

    配分額:17810000円 ( 直接経費:13700000円 、 間接経費:4110000円 )

    ホウ素中性子捕捉療法(BNCT)は、難治性がんの治療法として期待されている。本研究では、BNCT実用化に向け切望されている、様々ながんに対する特異的で高導入効率をもつホウ素製剤の開発を目指す。従来のホウ素製剤とは異なる、導入率を高めるために開発中の多量体ホウ素化合物に腫瘍標的ペプチドを結合させた全く新しいタイプのホウ素試薬を作製する。作製したホウ素試薬を用い腫瘍モデル動物で照射を行い効果を検証する。予想される成果が得られれば、「テーラーメイド型の粒子線治療」の実現に向け大きな一歩となる。

    researchmap

  • 腫瘍選択的高LET高RBE粒子線治療による治療抵抗性グリオーマ幹細胞制圧の試み

    研究課題/領域番号:23390355  2011年04月 - 2014年03月

    日本学術振興会  科学研究費助成事業 基盤研究(B)  基盤研究(B)

    宮武 伸一, 川端 信司, 道上 宏之, 黒岩 敏彦, 梶本 宜永, 切畑 光統, 増永 慎一郎, 小野 公二, 中村 英夫

      詳細を見る

    配分額:18720000円 ( 直接経費:14400000円 、 間接経費:4320000円 )

    神経膠芽腫(GBM)株A172とこの細胞株より誘導しGSCで、CD133等のマーカーの変化確認しGSCのstemnessを確認した。この2種類の細胞株にほう素化合物非存在下で等物理線量のX線と中性子線を照射し、colony forming assay, gamma H2A assayでの細胞のダメージを評価した。本系における細胞障害の担い手は窒素中性子捕捉反応により生じる、高LET粒子線である陽子線であり、同一物理線量ではX線より細胞障害活性が高く、DNA double strand brake の効率も高いことを示した。すなわち、高LET粒子線はGSCのX線抵抗性を克服することを証明した。

    researchmap

  • 蛋白質セラピー法による脳腫瘍治療技術の開発と機能実証

    研究課題/領域番号:20249009  2008年 - 2010年

    日本学術振興会  科学研究費助成事業 基盤研究(A)  基盤研究(A)

    松井 秀樹, 道上 宏之

      詳細を見る

    配分額:50050000円 ( 直接経費:38500000円 、 間接経費:11550000円 )

    悪性脳腫瘍に対する新しい治療法"中性子捕捉療法(BNCT)"で用いるホウ素製剤を開発した。我々が開発したタンパク質セラピー法を利用しがん細胞内へ薬剤を導入するタイプと、ドラックデリバリー(DDS)技術を利用し薬剤を封入したナノカプセルをがん細胞へ選択的に導入するタイプ、の2種類である。両製剤ともに、培養脳腫瘍細胞および、脳腫瘍モデル動物を用いた実験で、がん細胞に選択的に導入された。今後の新たながん治療薬として期待される。

    researchmap

▼全件表示

 

メディア報道

▼全件表示